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“Children are either too short or too tall, too fat or too lean. Their 
adolescence is too early or too late: they have too little or too 
much hair. They are intellectually backward or stupid, even 
defective or epileptic. The sella turcica is too small or too large 
and its bedposts are of the wrong shape or may even coalesce. 
The pineal gland casts a shadow and must be causing trouble. 
The basal metabolism, laboriously calculated, is found to be a 
little low or a little high. All this needs attention and can be 
corrected by some whole-gland extract, usually with a pinch of 
thyroid thrown in.”  
 
Harvey Cushing in Disorders of the pituitary gland: Retrospective 
and prophetic (J Am Med Assoc, 1921;76:1721-1726)  
 
 
 
 
 
 
 
 
 
 
To Liselotte, Clara, Agnes and Erik 
  
  
ABSTRACT 
The overall aim of this thesis was to investigate the metabolic effects and long-term safety of 
childhood growth hormone (GH) treatment. In order to achieve this aim, the different projects 
consist of a two-part clinical trial on metabolic features linked to GH physiology and GH 
treatment as well as two large population-based cohort studies with focus on the long-term 
cardiovascular and cancer risks in previously GH-treated patients.  
In study I, the metabolic profile of 35 prepubertal children of short stature, between 7 and 10 
years of age, with stimulated peak GH levels in the lower normal range (7-14 µg/L) was 
compared to 12 age- and sex-matched control children of normal height and weight. The groups 
were compared using blood samples of fasting glucose and insulin, HbA1c, insulin-like growth 
factor I (IGF-I), insulin sensitivity using both homeostasis model assessment of insulin 
resistance (HOMA-IR) and frequently sampled intravenous glucose tolerance test (FSIVGTT), 
dual-energy x-ray absorptiometry (DEXA), microdialysis and stable isotope examination of 
glucose production and lipolysis. Few differences between the groups were found but the 
subgroup of children with the lowest GH peak levels demonstrated lower fasting insulin levels 
and signs of increased insulin sensitivity. 
In study II, the 35 short children from study I were subsequently randomized to three different 
doses of recombinant human GH (rhGH) treatment; low dose (11 µg/kg/d), standard dose (33 
µg/kg/d) or high dose (100 µg/kg/d), and followed for two years. The doses were blinded to 
both patients and the study investigators. The metabolic effects of the different treatment doses 
were analyzed by the same methods as in study I and a clear dose-dependent metabolic effect 
could be demonstrated, in particular for the high dose group regarding fasting insulin and 
different measures of insulin sensitivity. 
In study III, the long-term cardiovascular morbidity in childhood rhGH-treated Swedish 
patients between 1985 and 2010, due to isolated GH deficiency (GHD), small for gestational 
age (SGA) or idiopathic short stature (ISS), was investigated. Data on cardiovascular outcomes 
and important covariates were gathered for a total of 3,408 patients and 50,036 randomly 
selected controls matched on sex, age and county. Time to first cardiovascular event was 
analyzed by Cox proportional-hazard regression models and the study showed increased 
adjusted hazard ratios for the patients compared to the controls.  
In study IV, the long-term cancer incidence and mortality in a large meta-cohort of 
approximately 24,000 previously childhood rhGH-treated patients from eight European 
countries were investigated. The results did not support an overall carcinogenic effect of rhGH 
treatment but the significant trend of increased cancer mortality risk in relation to rhGH dose 
in patients with previous cancer and the indication of possible effects on bone cancer, bladder 
cancer and Hodgkin’s lymphoma requires further vigilance.  
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1 INTRODUCTION 
Growth hormone (GH) is produced by the somatotrophic cells of the anterior pituitary gland 
and has numerous important physiological effects concerning growth and metabolism in all 
vertebrate species. In humans, different pathological states of deficiency or excess of GH are 
found in both adults and children, which can consequently lead to disturbances of growth as 
well as other metabolic functions in the body.  
A common patient group within the field of pediatric endocrinology are children with short 
stature, in which the question of possible GH deficiency and treatment with GH is often 
raised. Several hundreds of thousands of children have been treated with GH worldwide, 
since its introduction more than fifty years ago, and the treatment indications have gradually 
expanded from the most severe cases of GH deficiency, when treatment was scarce, to at 
present include several conditions in which the associated short stature is not primarily 
thought to be due to deficient endogenous GH secretion. 
My own interest in this field started from a general interest in physiology and a more specific 
interest in growth and metabolism based on my clinical work with this patient group. An 
understanding of the widespread effects of GH on metabolism and its efficacy and potency of 
treating short stature, regardless of the underlying cause, also triggered my interest in the 
safety issues related to this treatment. The different projects included in this thesis are 
therefore focused on these topics with the attempt to increase our current understanding of the 
metabolic effects linked to GH as well as our knowledge of the long-term safety of childhood 
GH treatment.  
Even if many patients have been treated with GH to this date, the current evidence of its long-
term safety is still uncertain due to the lack of long-term follow-up studies. The treatment 
effect on longitudinal growth has been extensively described over the years and large post-
marketing surveillance studies have suggested its short-term safety. However, the long-term 
safety of childhood GH treatment is still, to a large extent, uncertain and a central aim of this 
thesis is to bring more clarity to this issue. 
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2 BACKGROUND 
 
2.1 HISTORICAL BACKGROUND 
The conception of a pituitary-derived substance and its relation to growth dates back to the 
late 19th century. In 1886, the French neurologist Pierre Marie described a condition with 
abnormal growth of the hands, feet and the face which he proposed to call “acromegaly”, 
from the Greek words for extremities (“akro-”) and enlargement (“megalos”).1 Earlier 
description of this condition can be traced even further back to the 16th and 17th century with 
several names given to describe its features, such as “géant scrofuleux”, “prosopo-ectasia” or 
“macrosomia”.2 Marie continued his work to meticulously describe the phenotype of 
acromegaly but the etiology was still largely unknown, even if he pointed out that all cases 
had a “hypertrophy of their pituitary body with enormous dilatation of the Sella turcica”.3 
This observation was also supported by others, such as Dr. Oskar Minkowski in 1887.4  
Gradually during the coming years, several 
descriptions of abnormalities in the sella 
region was correlated to this condition and 
in 1892 the physician Roberto Massalongo 
could further describe the association with 
increased pituitary function in an 
acromegaly patient shown to have a 
pituitary tumor containing specific 
granulated cells.5  
However, it was not until the beginning of 
the 20th century that an agreement regarding 
the pathogenesis of acromegaly developed, 
in which it was attributed to hyperactivity 
of the pituitary gland and that gigantism 
had the same pathogenic mechanism but 
developed earlier in life before the 
epiphyseal fusion.6  
 
 
Figure 1. The two French brothers with gigantism 
(measuring 230 cm) posing with a person with 
pituitary dwarfism (measuring 69 cm) in a historical 
postcard 
Source: Reproduced from Enderle A. Dwarfism and 
gigantism in historical picture postcards. J R Soc Med. 
1998;91:273-278. 
 
Around the same time as the understanding of the pathogenesis of acromegaly and gigantism 
developed, the connection of extreme short stature (dwarfism) and pituitary dysfunction was 
suggested independently by Hutchinson and Benda in 1900.7  The idea that the same cells 
that created acromegaly or gigantism if overactive, also led to dwarfism if underactive, was 
further suggested by the Austrian physiologist Bernard Aschner8 and the American 
 4 
neurosurgeon Harvey Cushing coined the terms hyper- and hypopituitarism in 19099 and 
referred to “the hormone of growth” in his celebrated monography The Pituitary Body and its 
Disorders from 1912.10
Aschner published extensive studies on 20 
hypophysectomized dogs with a clear 
description of growth arrest in these animals 
and became convinced that the pathogenesis 
of acromegaly must be caused by a hyper-
function of the pituitary gland rather than 
hypo-function that had been suggested 
earlier by several other authors. In addition, 
Cushing’s systematic exploration of the 
pituitary gland and its function, in both 
clinical cases and animal experiments, 
contributed greatly to expand the scientific 
knowledge of this gland, its hormones yet to 
be discovered, and its interaction with the 
hypothalamus.11  
 
 
Figure 2. Harvey Cushing in 1938  
Source: Wellcome Trust Library  
In the coming decade, advances in the understanding of the connection between the pituitary 
gland and growth disorders continued through experimental hypophysectomies on different 
animal models. In tadpoles, Dr. Philip Smith reported an almost complete cessation of growth 
and also the reduction in size of the thyroid and gonads in the hypophysectomized animals.12 
In a later issue of Science the same year (1916), Bennet Allen described experiments with 
similar findings of growth retardation, change in pigmentation and striking retardation of 
limb development.13 In the following years, Smith could further demonstrate that the 
phenotype could be reversed by grafts of the anterior pituitary lobe and later also by extracts 
from bovine anterior pituitary lobes.7   
Perhaps this innovative work of Smith at the Anatomy department of the University of 
California in Berkeley inspired the head of the department, professor Herbert M. Evans, to 
take interest in the field. Together with his associate Joseph Long, Evans published a classical 
and groundbreaking study in 1921 in which they established the growth-promoting effects in 
rats by administration intraperitoneally of “finely ground, fresh anterior lobe of the 
hypophysis of beef”.14 At the 333rd day of life the treated rats where more than twice as heavy 
as the control animals and the authors concluded that “it would not appear to be incorrect to 
characterize these changes as producing constantly a certain degree of true gigantism”.14 
They also demonstrated that no effect was seen if this was given orally or if they received 
posterior hypophyseal substance instead.  
  5 
Some years later, in 1927, Smith could further support these findings in rats by demonstrating 
that hypophysectomy induced the “pituitary syndrome”; including growth inhibition (in the 
young) and cachexia (in the adult), atrophy of the genital system, loss of libido, atrophy of the 
thyroid, parathyroid and suprarenal cortex as well as general weakness and physical 
impairment.15 He could thereafter completely reverse this picture by transplanting gland 
material from adult rats intramuscularly with an “immediate and striking” response.15   
It would take an additional 20 years of extensive work before Evans together with his 
associate the biochemist Choh Hao Li finally in 1944 could isolate the substance from the 
anterior pituitary gland which promoted growth in hypophysectomized animals.16 They could 
also demonstrate in their female rats that the “the product did not show lactogenic, 
thyrotropic, adrenocorticotropic, follicle-stimulating or interstitial-cell stimulating activities, 
indicating that the preparation was substantially free of other biologically active pituitary 
contaminants”.16 Li continued to dedicate his life to the purification and determination of the 
molecular structure of several of the hormones from the pituitary gland17 and could in 1971 
together with Jonathan Dixon publish the primary molecular structure of growth hormone.18   
 
 
Figure 3. The amino acid sequence of the human growth hormone molecule published by Li and Dixon in 1971  
Source: Reprinted from Archives of biochemistry and biophysics, 1971;146. Li CH, Dixon JS. Human pituitary growth hormone 
XXXII. The primary structure of the hormone: revision, pp. 233-6, Copyright (1971), with permission from Elsevier. 
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2.2 THE BIOCHEMICAL STRUCTURE, REGULATION AND SIGNALING OF 
GROWTH HORMONE 
2.2.1 The human growth hormone gene 
The human GH gene (GH1) is part of a cluster of five similar genes connected to growth on 
the long arm of chromosome 17 (17q23.3) and expressed in the somatotrophic cells of the 
anterior pituitary gland.19 The gene GH2 is situated at the same locus and encodes for a 
variant of hGH (hGH-V) exclusively expressed in the syncytiotrophoblasts of the placenta 
during fetal development.20 The remaining homologous genes in the region, CSHP (chorionic 
somatomammotropin pseudogene), CSH-1 and -2 (chorionic somatomammotropin gene), are 
also exclusively expressed in placental tissue and act in concert with hGH-V to stimulate the 
development and growth of the fetus.19,21  
The expression of GH1 is regulated by a proximal promotor region with a high level of single 
nucleotide polymorphism and a locus control region located between 14.5 to 32 kb upstream 
from GH1.22 Moreover, numerous transcriptional factors, coded by genes such as POU1F1, 
PROP1 or OTX2, are involved in the development of the pituitary gland and different 
mutations in these genes have been shown to disturb its normal development and function.23  
 
2.2.2 The biochemical structure of human growth hormone 
The main form of human growth hormone (hGH) consists of 191 amino acids in a single 
chain polypeptide with a molecular weight of 22-kilodalton (kDa). The major structural 
features are its four α-helices, hydrophobic core, and two disulphatic bonds between cysteine 
at position 53 and 165 and cysteine at position 182 and 189.24,25 Other isoforms of hGH exist 
by alternative mRNA splicing of the 217-amino acid GH-precursor, such as a 20-kDa 
isoform lacking residues 32 to 46.26 The principle 22-kDa isoform constitutes approximately 
90% of the different isoforms in the circulation and it is still unclear if the other forms of 
hGH has any substantial functional difference.27,28 
 
 
Figure 4. The three dimensional structure of human 
growth hormone published in Science by de Vos et al 
in 1992 
Source: From de Vos A, Ultsch M, Kossiakoff A. Human 
growth hormone and extracellular domain of its receptor: 
crystal structure of the complex. Science (New York, NY) 
1992;255:306-12. Reprinted with permission from AAAS. 
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2.2.3 The regulation of growth hormone secretion 
GH is secreted from the anterior pituitary gland in a pulsatile fashion approximately every 
three hours, predominantly during the night, with maximum peaks shortly after the first onset 
of slow-wave sleep (stages III and IV).29,30 The secretion pattern is under hypothalamic 
control by the stimulatory peptide GH releasing hormone (GHRH) and the inhibitory 
counterpart somatostatin.31 GHRH stimulates both synthesis and release of preformed GH but 
somatostatin only inhibits its release.31 The troughs (low points) of GH release is to a large 
extent affected by the “somatostatin tonus” and its disinhibition is a permissive factor for the 
timing and amplitude of the recurrent GH pulses.32 
In 1999, an additional important stimulatory peptide was discovered, ghrelin (the name given 
from the proto-Indo-European word “ghre” meaning growth), which stimulates GH release 
both directly and indirectly through GHRH and somatostatin.33 The 28 amino acids long 
peptide was identified as the ligand to the already known GH secretagogue receptor (GHS-R) 
and was found to mainly be expressed in the stomach but also to some degree in the 
hypothalamus.34 In high doses, ghrelin can additionally stimulate release of other pituitary 
hormones (ACTH, prolactin) and is involved in several other physiological processes, such as 
stimulating appetite, gastric acid secretion, gastric motility, and insulin secretion if coupled 
with high blood glucose levels.35  
The secretion of GH is also regulated by a classical negative feedback loop by its prime 
mediator of its physiological effects, insulin-like growth factor I (IGF-I), which inhibits GH 
secretion both directly at the pituitary level36,37 and indirectly by affecting GHRH and 
somatostatin signaling at the hypothalamic level38,39. GH have, in addition, a negative effect 
on its own secretion by inhibiting GHRH expression at the hypothalamic level.40,41 
Many other factors also contribute to the complex regulation of GH release, ranging from a 
number of individual and environmental factors, such as stress42, exercise43, hypoglycemia44, 
fasting45, obesity46, age47, to other hormonal factors, such as the influence of sex steroids48, 
leptin49, glucocorticoids50, and more.  
A schematic picture including some of the major factors regulating GH secretion is presented 
below.
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Figure 5. Schematic overview of the regulation of growth hormone secretion by some of the described central 
and peripheral neuroendocrine signals 
Source: Reprinted by permission from Springer Nature: Nature Reviews Endocrinology, Glucocorticoids and the regulation 
of growth hormone secretion, Mazziotti G, Giustina A, Copyright (2013).
2.2.4 Growth hormone signaling 
The intracellular effects of GH are initiated through the binding to its cell surface receptor; 
the growth hormone receptor (GHR). The GHR is considered an archetypical cytokine 
receptor51 being the first cytokine receptor to be purified and cloned in 1987 by Leung et al.52 
The receptor is a protein of 620 amino acids with an extracellular domain of 246 amino acids, 
a single 24 amino acid transmembrane helix and an intracellular domain consisting of 350 
amino acids.52,53 The gene coding for GHR is located on chromosome 5 (p13.1-p12), contains 
10 exons of which nine are coding, and is expressed in many tissues but most abundantly in 
the liver.24,54,55 
A circulating binding protein for GH (GHBP) was identified in 1986, just a year before the 
discovery of the GHR, and was later found to be identical to the extracellular domain of the 
GHR.56 In rodents GHBP is generated by alternative splicing, but in humans through 
proteolysis of preformed GHR by the tumor necrosis factor-α-converting enzyme (TACE) 
and subsequent shedding of its extracellular domain to the circulation.57 Its circulating 
concentration is thus believed to reflect the overall GHR expression status. Approximately 
50% of circulating 22-kDa GH is bound to GHBP which prolongs the half-life of GH and 
serves as a buffer of GH in the circulation and at different target tissues.58,59 It has been 
suggested that GHBP entails both inhibitory and stimulatory effects in GH signaling but its 
complete role is still uncertain.60   
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It was initially believed that the trigger for the intracellular signaling was the dimerization of 
the GHR induced by the binding of the GH molecule to the receptor.61,62 However, it has later 
been shown that GH rather binds to the two different binding sites of a pre-formed dimerized 
receptor, and thereby a rotation of one of the receptor subunits is induced.63,64 This 
conformational change enables the intracellular Janus kinase 2 (JAK2) to be repositioned, 
exposing its enzymatic kinase domain and triggering an intracellular signaling cascade by 
phosphorylating a conserved tyrosine in the cytoplasmatic signal transducers and activator of 
transcription proteins (STATs), particularly STAT5b.65 The activation of STATs enables 
them to form homo- and heterodimers that in turn can translocate to the cell nucleus and 
promote the transcription of several GH target genes involved in growth and metabolism.66,67 
 
 
Figure 6. Intracellular signaling pathways of growth hormone 
Source: Reprinted by permission from Springer Nature: Nature Reviews Endocrinology, The growth hormone receptor: 
mechanism of activation and clinical implications, Brooks AJ, Waters MJ, Copyright (2010). 
 
The binding of GH to the GHR triggers additional intracellular pathways illustrated above; 
the Src family kinases proto-oncogenes activate the mitogen-activated protein kinase 
(MAPK)/extracellular signal-regulated kinase (ERK)-pathway and the insulin receptor 
substrate (IRS) activates the phosphoinositide-3-kinase (PI3K)-AKT-mTOR-pathway, both 
highly involved in cell proliferation, metabolism and cell survival.68-70 
 
2.2.5 GH/IGF-I-axis - the somatomedin hypothesis 
The origin of the “somatomedin hypothesis” dates back to the landmark study by Salmon and 
Daughaday in 1957, in which they suggested that the effects of GH, or somatotropin as the 
hormone also has been referred to, was mediated through some other circulating factor.71 This 
 10 
factor was called “sulphation factor” based on its ability to stimulate cartilage sulphate uptake 
in both in vivo experiments of hypophysectomized rats and in vitro studies using costal 
cartilage of rats. They could demonstrate that the incorporation of radioactive sulphate in rat 
cartilages was reduced in hypophysectomized rats but could be restored by adding serum 
from normal rats or GH-treated hypophysectomized rats, in contrast to serum from non-GH-
treated hypophysectomized rats or GH directly to the medium. Hence, the name “sulphation 
factor” for this unknown substance mediating the anabolic effects of GH in skeletal tissue. 
The term somatomedin was later coined by Daughaday et al in 1972 to emphasize that this 
substance was increased by GH (somatotropin) and mediated the effects peripherally in both 
skeletal and non-skeletal tissue.72 At that time, an understanding of the insulin-like properties 
of somatomedin, and its similarity to another described substance with non-suppressible 
insulin-like activity (NSILA) by Froesch and colleagues, was beginning to emerge.73,74 
Further investigations could establish that the newly determined peptides with NSILA, named 
insulin-like growth factor (IGFs) I and II, were identical to somatomedin type C and A and a 
universal nomenclature was proposed.75 Later research findings have modified the original 
somatomedin hypothesis by illustrating a more complex relationship with both indirect 
effects of GH through IGF-I in an endocrine, paracrine and autocrine manner and direct 
effects on different tissues independent of IGF-I.76-78  
 
Figure 7. The revised somatomedin hypothesis including both direct and indirect effects of growth hormone and 
non-canonical targets 
Note: SSTN = Somatostatin, APG = Anterior Pituitary Gland, GHRH = Growth Hormone Releasing Hormone, GH = Growth 
Hormone, IGF-1 = Insulin-like growth factor I 
Source: Reprinted from Kumar PA, Menon RK. New insights into growth hormone action on the macrophage: implications 
for non-growth-related actions of growth hormone. OA Biochemistry 2013 Oct 20;1(2):15. 
 
  11 
2.2.6 Insulin-like growth factors  
The peptides IGF-I and IGF-II are highly evolutionary conserved proteins of 70 and 67 amino 
acids each, with significant structural homology to proinsulin and crucial for regulating 
growth and metabolism in many cell types.79 There are two known IGF receptors but both 
IGF-I and IGF-II bind primarily to the type 1 receptor (IGF1R) which has a sequence 
similarity varying between 41% to 84% to the insulin receptor, depending on the domain (the 
highest in the enzymatically active kinase domain).80,81  
The majority of IGF-I in the circulation (up to 75%) is produced by the liver but virtually all 
tissues in the body can produce IGF-I, illustrating its important autocrine/paracrine capacity 
in addition to its endocrine properties.77,82 IGF-II is in general considered to primarily be of 
importance for prenatal growth, illustrated by IGF-II-gene knockout mice models83,84 and the 
genetic/epigenetic alterations in IGF-II-related human disorders such as Silver-Russell 
syndrome85 or Beckwith-Wiedemann syndrome86. However, recent attention to its postnatal 
metabolic actions and links to obesity, type 2 diabetes and cardiovascular disease is also  
emerging.87-89  
In the circulation and local tissue, the majority of the IGF molecules are bound to one of its 
six known binding proteins (IGFBP1-6) that can prevent the degradation of IGFs, modulate 
its action, facilitate transport and, to some extent, independently affect cell migration and 
proliferation.90-92 The most abundant of the IGFBPs, and with the highest affinity for IGF-I, is 
IGFBP3. Together with another protein also produced by the liver, the Acid Labile Subunit 
(ALS), IGF-I, IGFBP3 (or IGFBP5) can form a large 150-kDa ternary complex which further 
increases the half-life of IGF-I, contains it in the circulation and prevents undesirable 
metabolic effects, such as hypoglycemia through binding to the insulin receptor.79,93 All these 
three proteins (IGF-I, IGFBP3 and ALS) are central for human growth and under the 
stimulatory control of GH secretion.94-96  
The hepatic production of IGF-I is to a large extent under the control of GH secretion but is 
also affected by nutritional intake97 and insulin levels in the vena porta circulation98 in which 
insulin affects GH-induced IGF-I production by stimulation of hepatic GHR transcription and 
translocation of GHR to the hepatic cell surface.99 IGF-I levels also naturally vary over 
different periods in life, with the highest levels during puberty, in which sex steroids 
stimulate both GH secretion, modulate its peripheral actions and, as a consequence, increases 
IGF-I synthesis.48   
 
2.3 PHYSIOLOGICAL EFFECTS OF GROWTH HORMONE 
GH comprises a multitude of physiological effects in the body throughout life, by direct 
effects through its receptor and by interacting with other hormones. The two main effects 
involve longitudinal growth and the metabolism of carbohydrates, proteins and lipids. These 
effects will briefly be discussed in the following sections.  
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2.3.1 Longitudinal growth 
Human growth can be divided into four separate phases; the fetal, infancy, childhood and 
pubertal phase, during which different factors such as genetics, nutrition, somatic and 
psychological well-being as well as hormonal factors contribute to various degrees.100-103  
In the fetal phase, maternal factors, such as maternal nutrition and health, uterine size and 
placental function, play an important role in addition to primarily the actions of IGF-I, IGF-II 
and insulin.104-106 The effect of congenital GH deficiency on birth size is quite limited but 
IGF-I deficiency will markedly impair intrauterine growth in both humans and animals, as 
shown in rare clinical conditions and knock-out mouse models.107-110 The importance of GH 
gradually becomes more central during the infancy phase and plays a key role throughout the 
childhood and pubertal phases.111-113 Several other hormones and growth factors are also 
important during the different phases of human growth, such as thyroid hormone, adrenal 
androgens, sex steroids, C-natriuretic peptide and fibroblast growth factors.114-116    
The longitudinal growth promoting effects of GH and IGF-I within the growth plate is 
believed to be achieved by several mechanisms: recruitment of progenitor cells, increased cell 
division in the resting and proliferative zone, increased chondrocyte cell volume in the 
hypertrophic zone and stimulation of endochondral ossification.117-122 The net effect is bone 
elongation and the current predominate conception is that GH has both IGF-I-dependent and 
IGF-I-independent actions in promoting its effects on bone growth.123,124 
 
2.3.2 Metabolic effects 
Although GH has received its name for its growth promoting effects, it is also highly 
involved in the body’s metabolism of lipids, carbohydrates and proteins.125 It executes these 
effects in various ways in different tissues, both directly and indirectly through interaction 
with mainly IGF-I and insulin.126,127 From an evolutionary perspective, GH has an important 
role in regulating what energy fuel is used at different nutritional states, steering it away from 
carbohydrate and protein usage towards predominantly lipid usage. In short, GH promotes 
nitrogen retention, enhancing protein synthesis, in periods of food intake and alters the energy 
substrate from glucose and protein utilization to lipolysis in periods of fasting.128  
 
2.3.2.1 Growth hormone and lipid metabolism 
GH has a prominent lipolytic effect and a single dose of exogenous GH will distinctly 
increase the amount of free-fatty acids (FFA) and ketone bodies in the circulation.129 GH 
stimulates lipolysis in the adipose tissue primarily through stimulating the activity of 
hormone-sensitive lipase (HSL).126,130 However, the effect on lipoprotein lipase (LPL) has 
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been shown to be either suppressive or non-existent suggesting that GH plays a minimal role 
in the lipid uptake of the adipose tissue.131 In contrast, LPL expression is upregulated by GH 
in skeletal muscle which induces uptake of FFA and thus promotes lipid utilization as fuel in 
the muscle.132 The same mechanism is also seen in the liver where GH also promotes uptake 
of FFA by stimulating hepatic lipase (HL) activity.133,134 
 
2.3.2.2 Growth hormone and protein metabolism 
The overall effect of GH on protein metabolism is anabolic both by its effects on protein 
synthesis and degradation but also by its effects on increasing the amount of alternative 
substrates for gluconeogenesis and thus diminishing the need of proteolysis.135 In basal and 
periprandial states, most studies suggest a modest anabolic action of GH on protein 
metabolism, in contrast to states of stress and fasting where it has a more clear protein-
preserving ability.127 However, the main effects on protein synthesis and inhibition of muscle 
protein breakdown seem to be primarily mediated through IGF-I and insulin.136 
 
2.3.2.3 Growth hormone and carbohydrate metabolism 
Already in the initial descriptions of acromegaly, the connection of GH to carbohydrate 
metabolism was noted, as these patients often developed diabetes.3,137 However, the most 
important contributions to clarify the metabolic effects of GH on carbohydrates were carried 
out by Dr. Bernardo Houssay and his team in the 1920s to 1930s, where they in 
hypophysectomized dogs observed fasting intolerance with severe hypoglycemia, high 
sensitivity to insulin and a diabetogenic effect of anterior pituitary extract injections in both 
normal and hypohysectomized dogs.138,139 They could further show that the increased insulin 
resistance from administrating extracts of the anterior lobe was also seen in animals without 
pancreas, gonads, thyroid or adrenal glands, indicating an independent mechanism of action 
rather than secondary effects on other hormonal systems.  
Dr. Houssay was in 1947 awarded with the Nobel Prize in Physiology or Medicine for his 
ground-breaking work with the motivation: “for his discovery of the part played by the 
hormone of the anterior pituitary lobe in the metabolism of sugar”.140 His findings were later 
confirmed in several famous studies by Frank Young, who induced diabetes in healthy dogs 
by injecting anterior lobe extracts and in 1937 stated that the “permanent diabetes produced 
in this manner differed from that of depancreatised dogs in that the pituitary dogs appear to be 
able to survive without insulin”.141  
The effects on carbohydrate metabolism have later been found to be rather complex and 
presumably also linked to the dominant lipolytic effects of GH. It has in clinical studies been 
shown that infusion of GH decreases the uptake of glucose in skeletal muscle and decreases 
glucose oxidation probably due to an increase in lipid utilization in the muscles.142 In the 
liver, GH stimulates hepatic glucose production by increasing glycogenolysis and to a lesser 
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degree gluconeogenesis.126,143 Lastly, GH also affects insulin secretion and signaling (see 
next section), further contributing to an overall increased insulin resistance and making it 
somewhat hard to disentangle the different contribution of direct effects on hepatic glucose 
production and indirect effects through increased hepatic and peripheral insulin resistance. 
 
2.3.2.4 Growth hormone and insulin resistance 
Several mechanisms on how insulin resistance is induced by GH have been suggested, 
including both increased endogenous glucose production144,145, decreased glucose uptake in 
muscle tissue146, as well as effects on insulin signaling147-149. Thus, GH is believed to 
influence both hepatic and peripheral insulin sensitivity. Several of these effects may be due 
to the lipolytic effect of GH150,151, as mentioned above, which results in an increase of FFA 
and a shift in substrate usage for muscle tissue, as well as potential post-receptor effects on 
insulin signaling147,152 and effects on β-cell insulin secretion153,154. However, GH has also 
been shown to have direct effects independent of the increase of FFA143, possibly through 
negative effects on the insulin receptor and the common post-receptor signaling pathway of 
insulin and GH, involving IRS and PI3K.148,149  Even if there is a net effect on both lower 
glucose uptake in peripheral tissue as well as increased endogenous glucose production, the 
strict homeostatic control of serum glucose levels is maintained by higher levels of insulin 
secretion. One could speculate regarding a possible physiological advantage in creating a 
state of insulin resistance in order to not only attain the glucose regulating effects of insulin 
but also its anabolic effects in different phases of growth.  
 
2.3.2.5 Metabolic profile of growth hormone deficient children 
As a consequence of the physiological effects of GH described above, severe deficiency of 
GH is associated with several metabolic features such as deranged body composition due to 
reduced lipolysis155-157 and impaired protein anabolism127 as well as decreased hepatic 
glucose production158 and increased peripheral glucose uptake due to increased insulin 
sensitivity159. In the early works of Goodman et al, the clinical features were described as 
severely stunted patients with immature, doll-like facial appearance, with notably increased 
central fat deposits “giving a pudgy appearance”, small external genitalia and increased risk 
of hypoglycaemia.156  
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Figure 8. Clinical features of severe growth hormone deficiency  
Note: CA = Chronological Age, HT = Height, HA = Height Age, BA = Bone Age. 
Source: Reproduced with permission from Goodman HG et al. Growth and growth hormone. II. A comparison of isolated 
growth-hormone deficiency and multiple pituitary-hormone deficiencies in 35 patients with idiopathic hypopituitary 
dwarfism. The New England Journal of Medicine 1968;278:57-68. Copyright Massachusetts Medical Society. 
 
Severe GHD is fortunately a rare condition and the majority of pediatric patients referred to 
endocrinologists due to short stature do not present with this phenotype. Nevertheless, quite 
few studies have investigated the metabolic features of short patients with less severe GHD.  
An exception to this, is however a study by Husbands et al, who reported that children with 
GHD, despite higher BMI, were more insulin sensitive than short children with normal GH 
secretion.159  In addition, numerous studies examining the metabolic effects of GH treatment 
have demonstrated a decrease in insulin sensitivity, resulting in increased levels of insulin and 
C-peptide 160-162, with only limited effects on fasting glucose and HbA1c in some studies163  
but also effects on these parameters in more recent investigations.164-168 
A summary table of the major physiological effects of the GH/IGF-I-system in different 
tissues is presented below. 
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Table 1. Physiological effects of GH/IGF-I in different tissues 
Organ Main effect Mechanism Ref 
Bone/growth plate Promotes longitudinal 
bone growth 
 
 
Stimulation of chondrocyte progenitor cells 
and the proliferation and differentiation of 
prechondrocytes through stimulation of 
systemic and local IGF-I synthesis as well as 
by IGF-independent mechanisms.  
117,118,120-
122 
 Regulates bone 
remodeling 
Stimulation of osteoblast proliferation and 
differentiation and, together with IGF-I, the 
recruitment and activity of osteoclasts. 
169-172 
Liver Increases hepatic 
glucose production 
Stimulation of glycogenolysis and (to some 
extent) gluconeogenesis, as well as increased 
hepatic insulin resistance. 
143,144,173-
175 
 Decreases hepatic 
insulin sensitivity 
Downregulation of insulin receptor and 
impairment of post-receptor insulin signaling. 
147-149
 
 Increases uptake of 
triglycerides  
Stimulation of hepatic lipase activity. 133,134 
Adipose tissue Increases lipolysis Stimulation of hormone-sensitive lipase 
(predominantly in the visceral adipose tissue 
and to some degree in the subcutaneous 
adipose tissue). 
126,130
 
 Decreases glucose 
uptake 
Downregulation of glucose transporter-1 
(GLUT-1). 
126
 
Skeletal muscle Decreases glucose 
utilization 
Decreased glucose uptake and glucose 
oxidation. 
129,146
 
 Increases lipid 
utilization 
Upregulation of LPL and FOXO1 expression 
leading to increased lipid uptake and 
triglyceride synthesis. 
131,132
 
 Impairs insulin 
signaling 
Reduction of insulin receptor and IRS-1 levels 
with inhibition of the IRS/PI3K-pathway and 
induction of insulin resistance due to increased 
levels of FFA. 
147-152 
Pancreas Increases insulin 
secretion 
Stimulation of β-cell proliferation and insulin 
secretion. 
153,154
 
  17 
2.4 GROWTH HORMONE TREATMENT 
2.4.1 The history of growth hormone treatment 
Treatment with human GH has been in clinical use since the late 1950s and in a recombinant 
form since the mid-1980s.176 However, attempts to treat human dwarfism with “purified” GH 
from bovine pituitaries started already in the 1930s, although with meager results.7 The idea 
of GH as a species-specific hormone was postulated and the promising results of porcine and 
bovine insulin treatment in humans was not repeated with GH. The final proof of the “species 
specificity”-hypothesis was delivered by Ernst Knobil and Roy Greep in a famous study in 
Rhesus monkeys where they could demonstrate that primates would only respond to primate 
GH.177 It has later been shown how this specificity is related to a single change in the amino 
acid chain of the GH protein which restricts the human GH receptor to only interact with GH 
of humans or other primates.178 
In the end of the 1950s, the first purified preparation of human GH was described by Li and 
Papkoff179 and the year after a simplified and more effective method was described by 
Raben180. In practice, the extracting and purifying process of GH from human cadaveric 
pituitaries was still a very costly and labor-intensive task in order to produce an effective 
amount of pituitary extract for treatment.181 In the early days, approximately only 1 mg of 
hGH could be extracted from each pituitary gland and since that was roughly the same 
amount needed to treat one patient for one day, a total of 365 pituitary glands were needed for 
only one patient’s yearly treatment requirements. In 1963, an improved extraction and 
purification method using gel filtration was developed and published by the Swedish chemist 
Paul Roos et al182 and the amount of hGH that could be extracted from a single pituitary 
gland continued to steadily increase during the 1970s due to further improvements in the 
purification process.181 In the same decade, advances in identifying the biochemical structure 
of GH and the cloning of the GH gene for the first time in 1979 lay the groundwork for 
development of recombinant DNA-derived hGH.176 
In 1985, the first reports of Creutzfeldt-Jakob Disease (CJD), in patients that had previously 
been treated with pituitary-derived GH, started to emerge and over the following years more 
than 200 cases related to contaminated cadaveric-derived treatment have been seen 
worldwide.183 The majority of cases (119 of 226) have been reported from France and 
especially originating from a treatment period from December 1983 to July 1985.183 
However, around the same year, recombinant hGH (rhGH) became available for treatment 
and all use of pituitary-derived GH ceased. This was not only a major breakthrough in 
providing a “clean” substance to the patients with severe GHD but also creating a possibility 
of unlimited supply of GH, enabling the expansion of treatment indications to a larger 
number of patient groups. 
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2.4.2 Treatment indications and diagnostic challenges 
From being an exclusive treatment given only to the most severe cases of GHD, when the 
supply was scarce, the advances in producing rhGH also made it possible to expand to less 
severe GHD patients as well as to other treatment indications. Current indications for GH 
treatment* also include an increasing number of conditions in which childhood short stature is 
not primarily due to deficient endogenous GH secretion.184-186 Examples of such conditions 
are idiopathic short stature, renal failure, Turner syndrome, or children born SGA. Conditions 
in which growth failure is a common feature but not assigned to defects in the GH/IGF-I-axis, 
thus expanding the indications from being a strict replacement therapy to also include a sort 
of “height enhancement therapy” for those patient groups.187   
However, GHD is still the major treatment indication but this diagnose can also be quite 
challenging to determine.188 Growth hormone is, as earlier described, secreted from the 
pituitary gland in a pulsatile manner with a very short half-life and often undetectable levels 
during large portions of the day. Thus, the diagnosis requires a combination of both clinical 
features, auxological patterns, information about parental height, investigation for other 
conditions leading to growth failure, possibly neuro-imaging as well as measurements of GH 
peak levels in response to different stimulation tests or spontaneous GH secretory profiles 
over 12 to 24 hours. Diagnosing the severe cases of GHD is often less challenging but those 
cases are rare and GHD can be considered as a continuum from total lack of secretion to less 
severe deficiency and borderline normal secretion.188 Defining an adequate peak GH cut-off 
level for GHD in different stimulation tests has also been difficult due to large inter-assay 
variability in the assays measuring GH, different standardizations of the assays over time as 
well as considerable intrapersonal variability in the measurements.189-191  
In the 1960s, GHD was defined as stimulated GH peak concentrations below 3 µg/L but over 
time the cut-off level gradually increased to 7 µg/L and later 10 µg/L.191 Today, a stimulated 
GH-peak <7 µg/L is frequently used for defining GHD but a cut-off level of 10 µg/L is also 
often seen when GHD is distinguished from non-GHD forms of short stature, i.e. idiopathic 
short stature (ISS) or familial short stature (FSS).184,188 The use of different standards for GH 
assay calibration have further complicated the issue. The introduction of recombinant 
calibration standards produced lower GH concentration values compared with the older 
pituitary-derived standards192-194 and the conversion from different units (mU/L to µg/L) have 
added an additional source of error where large variations have been shown.195,196  
The proposed continuum of GHD from total/severe deficiency to borderline/normal secretion 
is analogously illustrated in the responsiveness of GH treatment, where patients with severe 
GHD are highly responsive and patients with less severe GHD or ISS are not as 
responsive.197 The difference of response could of course be due to several reasons; such as 
                                                 
* The term “GH treatment” will throughout this thesis be used synonymously with “recombinant human GH 
treatment” unless otherwise specified as pituitary-derived human GH treatment. 
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lack of compliance, difference in the degree of GHD as stated above, and variability in a 
certain patient’s tissue responsiveness to GH.188 With regards to the variability in response to 
a certain GH dose, a shift from fixed dosing to more individualized dosing is currently more 
common, adjusting the dose based on height and IGF-I response or alternatively using 
prediction model-based dosing in which different parameters, such as GH-peak in stimulation 
tests, growth velocity, IGF-I levels, difference in height standard deviation score (SDS) 
versus mid-parental height SDS, are taken into account.198-201 However, to further complicate 
matters, maybe not only the individual variation in responsiveness to a certain level of GH 
might impact its various effects but the different GH secretion patterns with periods of peaks 
and lows might also contain different physiological effects. Studies in rats have indicated that 
the periodic pulsatile secretory pattern of GH may have implications on its different actions, 
where suggestively the peaks primarily affect growth and low periods in-between certain 
metabolic actions.202 How this translates to humans is however still uncertain.    
Lastly, the majority of patients that have received a GHD diagnosis in childhood based on 
abnormal stimulation test results will not have low GH-peak levels when re-tested after 
completion of growth.203-205 This seems particularly true for those with idiopathic isolated 
GHD and with a normal magnetic resonance imaging of the pituitary gland. In one study, 
almost all (95%) childhood-onset idiopathic isolated GHD had normalized their stimulated 
GH peak response when retested.206  
In summary, the challenges of diagnosing GHD remain largely unsolved and the cut-off 
levels are, from a physiological perspective, in a sense arbitrary and also burdened with issues 
of low reliability. Some patients with total lack of GH secretion will more easily be 
diagnosed but the majority of GHD patients are in-between total deficiency and normal 
levels. Furthermore, large patient groups with growth failure due to other reasons than 
deficiency of GH are treated, rendering the treatment with rhGH to more than just a 
replacement therapy and also introducing new ethical dimensions to the treatment decision.207  
 
 
2.5 LONG-TERM SAFETY OF GROWTH HORMONE TREATMENT 
2.5.1 Effects of increased or decreased activity in the GH/IGF-I axis 
Based on the physiology of GH and its interaction with central mechanisms of growth and 
metabolism it seems clear that neither too much nor too little of GH is desirable in order to 
both develop normally and sustain a metabolism in balance. One way of better understanding 
the consequences of such disturbances and what potential long-term physiological effects 
they will have, is to study the “natural experiments” provided by Mother Nature, where 
activity in the GH/IGF-I axis is altered due to either acquired or congenital diseases. 
 20 
A previously mentioned example of GH excess is acromegaly, where patients due to a GH-
producing tumor of the pituitary gland have chronically increased and unregulated GH levels. 
This condition results not only in somatic overgrowth but also in impaired glucose tolerance 
with increased insulin resistance208, associated metabolic and cardiovascular morbidity209,210 
as well as an increased risk of colorectal tumors210,211.  Furthermore, colorectal tumors seem 
to be related to high GH and IGF-I levels, as those with severe and uncontrolled acromegaly 
have higher risks compared to those with well-controlled disease.212 Acromegalic patients 
have been reported to have a higher risk of cardiomyopathy, hypertension, arrhythmias, and 
type 2 diabetes mellitus (T2DM).210 Studies have also shown that acromegalic patients have 
vascular alterations213,214 and an increased risk to develop aneurysms215. In the last referenced 
study by Manara et al, it was also shown that the risk of developing aneurysms was positively 
associated with higher levels of GH at disease onset. 
A contrasting example, with decreased activity in the GH/IGF-I axis, are patients suffering 
from Laron syndrome, who due to mutations in the GH receptor have impaired GH-signaling 
with very low levels of circulating IGF-I. Clinical features are similar to severe GHD with 
pronounced short stature, a certain facial phenotype and marked obesity.216 However, despite 
their increased obesity, a recent study showed that subjects with Laron syndrome had lower 
incidence of T2DM, lower glucose and insulin concentrations and lower insulin resistance 
(measured by homeostasis model assessment of insulin resistance [HOMA-IR]).217 This 
observation suggests an important role of intact GH/IGF-I signaling in the development of 
obesity-driven insulin resistance.  
 
 
Figure 9. Ecuadorian cohort of patients with Laron syndrome together with their treating physician Dr. Jaime 
Guevara-Aguirre in 1988 (left) and 2009 (right)  
Source: From Guevara-Aguirre, J., et al. (2011). "Growth Hormone Receptor Deficiency Is Associated with a Major 
Reduction in Pro-Aging Signaling, Cancer, and Diabetes in Humans." Science Translational Medicine 3(70). Reprinted with 
permission from AAAS. 
 
Furthermore, studies from different Laron cohorts have also shown that their low activity in 
the GH/IGF-I axis seems to be protective of cancer development.218,219 A study218 from 2007 
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showed no malignancies in 222 patients with congenital IGF-I deficiency (169 patients with 
Laron syndrome and 53 with either GHRH receptor defects or GH gene deletion), with ages 
ranging from 3 to 78 years, and similar observations have been seen in two other studies219,220 
from 2011. These findings are also in line with a large systematic review published in The 
Lancet by Renehan et al, reporting an association between higher IGF-I and IGFBP-3 levels 
and increased risks of certain cancer types.221  
Lastly, several animal studies have shown that mice with low GH/IGF-I activity are prone to 
live longer and have reduced incidence and/or delayed onset of neoplasms and other age-
related pathologies.222-224 Few studies have been done in humans, but a study by Milman et al 
showed that low IGF-I levels increased the predicted life expectancy in extremely long-lived 
females but not males.225 For individuals with a previous history of cancer this association 
was seen for both males and females. Interestingly, this sex difference, with extended 
survival associated with lower IGF-I levels, has also been noted in other animal species.226  
From normal physiology and the more extreme examples mentioned above, one can conclude 
that the old Greek saying “pan metron ariston” (translated as “everything in moderation”) 
seems appropriate also for GH/IGF-I activity. However, different types of morbidities might 
be expected at the different ends of the activity spectrum with tumorigenesis and insulin 
resistance in the higher end of GH/IGF-I activity and short stature, dyslipidemia and obesity 
in the lower end. With respect to the expansion of GH treatment indications beyond mere 
supplementation therapy to more of a “height enhancement therapy” in certain patient groups, 
where the activity of GH/IGH-I is not necessarily impaired, additional attention of morbidity 
in the higher end of the spectrum seems appropriate. 
 
2.5.2 Surveillance of growth hormone treated patients 
The tragic events of Creutzfeldt-Jakob Disease in patients treated with pituitary-derived GH, 
described above, increased the awareness of the potential long-term risks and prompted the 
demand to closely monitor the patients treated with recombinant human GH. Several nation-
wide clinical treatment registries were initiated, such as the Swedish National Growth 
Hormone Registry, started in 1985, and in certain countries governmental agencies created 
mandatory registries of all patients started on rhGH treatment (e.g. Association Hypophyse in 
France). In addition, the pharmaceutical industry also initiated large registries of patients 
being treated with rhGH to closely monitor potential side effects and adverse events. 
Examples of such post-marketing surveillance registries are: 
 KIGS – Kabi International Growth Study (Pfizer) 
 KIMS – Kabi International Metabolic Study (Pfizer) 
 NCGS – National Cooperative Growth Study (Genentech) 
 GeNeSiS - The Genetics and NeuroEndocrinology of Short Stature International 
Study (Eli Lilly) 
 NordiNet IOS – International Outcome Study (Novo Nordisk) 
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 PATRO Children – The Patients TReated with Omnitrope® (Sandoz) 
Large number of patients have been included in these cohorts and several short-term side 
effects have been described, such as benign intracranial hypertension, epiphysiolysis, 
scoliosis, impaired glucose tolerance and pancreatitis.227-229 Still, the overall short-term safety 
profile of rhGH has been considered favorable and certain early alarms of potential increased 
risk of leukemia230 have not been seen in subsequent studies or in these post-marketing 
databases.227,231  
However, several limitations of these post-marketing studies have been pointed out, such as 
the reliance on voluntary reporting of treating physicians, incomplete enrollment and 
outcome ascertainment, potential conflicting interest with the hosting pharmaceutical 
companies that control the access, analysis and release of data as well as lack of suitable 
comparison and control groups.187,229,232 Moreover, the patients are only followed during their 
ongoing treatment which precludes the possibility to determine the long-term safety profile of 
the treatment and the possibility to discover rare events expected to manifest later in life. 
These limitations and the continuous need to more properly address the issue of long-term 
safety in GH-treated children inspired the joint collaboration of eight European countries in 
creating a large meta-cohort study called SAGhE (Safety and Appropriateness of Growth 
hormone treatments in Europe).232 The purpose was to analyze both efficacy on height, 
effects on quality of life as well as the long-term risks of future cancer incidence and 
mortality “independently of pharmaceutical companies”.232 
 
2.5.3 Alarms from the French SAGhE cohort 
On the 10th of December 2010, the European Medicines Agency (EMA) sent out a press 
release stating that the French Agency for the Safety of Health Products (AFSSAPS) had 
reported to them a suggested increased risk of mortality in patients treated during childhood 
with somatropin (GH).233 The Food and Drug Administration (FDA) also published a press 
release shortly thereafter about the preliminary results from the French study but later pointed 
out, in April 2011, several methodological shortcomings which made it hard to draw clear 
conclusions from the data.234 In the final report from EMA (EMEA/H/A-107/1287) in 
February, 2012, emphasis was also put on the limitations of the French study but that the 
results should be regarded as a potential safety signal and further surveillance was needed. 
These alarms stirred up a lot of emotions in the endocrine community and in 2012, Carel et al 
published their preliminary report showing an increased standardized mortality ratio (SMR) 
of 1.33 (95% CI; 1.08-1.64) of all-cause mortality in earlier treated subjects.235 They noted an 
increased mortality risk with higher doses of rhGH and particularly the risk for bone tumor-
related mortality (SMR 5.00, 95% CI; 1.01-14.61), diseases in the circulatory system (SMR 
3.07, 95% CI; 1.40-5.83) and subarachnoid or intracerebral hemorrhage (SMR 6.66, 95% CI; 
1.79-17.05). A brief report, published in the same issue of The Journal of Clinical 
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Endocrinology & Metabolism, from the SAGhE cohorts of Belgium, Sweden and The 
Netherlands was less alarming236 and the robustness of the results have been questioned as 
stated above.  
A study from 2016 by Albertsson-Wikland et al further elucidated this issue by showing that 
an observed increased SMR (1.43, 95% CI; 0.89-2.19) in Swedish childhood rhGH-treated 
patients with isolated growth failure (GHD, ISS or SGA without catch-up) normalized using 
a continuous hazard model also including birth characteristics (SMR 0.955, 95% CI; 0.591-
1.460).237 This illustrates the importance of trying to control for different confounding factors 
in these types of analyses. Nonetheless, the associations of these particular increased SMRs in 
the French cohort was disturbing, being both closely related to a central target tissue of GH 
(bone) and in unison with the previously reported link of increased activity of the GH/IGF-I 
axis and increased risk of cancer238,239 as well as cardiovascular and metabolic 
morbidity240,241.  
 
2.5.4 Growth hormone treatment and cardiovascular and metabolic 
morbidity 
From the studies of GH physiology, the acromegalic patients and the preliminary results of 
the French study above, concerns of long-term cardiovascular and metabolic morbidity seem 
warranted. However, the improvement of dyslipidemia, decrease of central adiposity and 
increase of lean body mass with GH treatment in GHD patients seem to point in the opposite 
direction. An argument of continued GH treatment in adulthood of these patients has also 
been made with intention of improving their cardiovascular risk profile.242  
A meta-analysis of placebo-controlled studies in GHD patients has indeed shown beneficial 
short-term (up to 1.5 years) effects of adult GH replacement treatment regarding body 
composition, diastolic blood pressure, LDL and total cholesterol but also negative effects on 
glucose and insulin levels.243 In contrast, a Dutch study from 2013, regarding the metabolic 
effects of long-term (>10 years) adult treatment with GH in GHD patients showed a 
significantly increased risk of developing the metabolic syndrome (mainly due to abdominal 
obesity, hypertriglyceridemia and hyperglycemia) which is strongly associated to 
cardiovascular morbidity.244 These conflicting results illustrate the complexity of this issue 
with potentially different mechanisms of developing insulin resistance, and a non-favorable 
metabolic profile, at hand.  
The risk of developing type 1 diabetes mellitus (T1DM) in GH-treated patients does not seem 
to be increased227,228 but in a study published in The Lancet by Cutfield et al, evaluating more 
than 23,000 GH-treated children, a 6-fold increase of type 2 diabetes mellitus (T2DM) 
incidence compared to two other age-matched cohorts of untreated children were reported.228 
Still being a rare event, the high increase in incidence and the lack of resolution even after 
GH treatment had been discontinued called for close monitoring of this potential 
consequence. When T2DM occurs in children or adolescents more than 80% are obese at 
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diagnosis but in the GH-treated children developing T2DM, obesity was much rarer, further 
supporting the idea of potentially a different pathogenic mechanism.  
A more recent large observational study investigating the incidence of T2DM and glucose 
metabolism in over 5,000 patients with adult-onset GHD treated with rhGH showed similar 
results.245 An increased incidence risk ratio (IRR) of 6.02 (p<0.0001) of developing T2DM in 
the treated group compared to the age- and sex-specific reference incidence rates in Sweden 
was reported. The increased IRR was largest the first year of treatment (10.8) to gradually 
decrease to 1.9 after 8 years of treatment. However, GH dose was not associated with 
development of T2DM but several other known risk factors were significantly associated, 
such as BMI, age, and waist-to-hip-ratio. This gradual decrease in the elevated IRR, with 
longer duration of GH treatment, could have several possible explanations; either that patients 
with higher risk of developing T2DM had an accelerated disease onset by treatment initiation 
or that there was an increased surveillance of blood glucose levels in the beginning of 
treatment which detected those at risk. One also needs to bear in mind the gradual increase of 
T2DM among young individuals in the background population when comparing incidence 
rates in treated cohorts with population-based incidence rates.  
In experimental studies, direct vascular effects of GH246 and IGF-I247 have been seen which 
together with observational studies, such as the French mortality study cited above, have 
raised concerns regarding the possible increased risk of cerebrovascular disease in GH-treated 
individuals. In a study by Poidivin et al248 these concerns were addressed and they reported 
an association of cerebrovascular morbidity (predominantly of hemorrhagic stroke) and GH 
treatment in childhood for isolated GHD or childhood short stature. However, this study has 
been criticized on several points, such as the use of questionnaires with low response rates 
and risk of responder bias, inappropriate comparison groups, questionable methods for 
compensating lack of exhaustive outcome data, and lack of important information regarding 
known and strong confounders (birth data such as birth weight and birth length).249,250  
The effect of GH treatment on cardiovascular risk factors is a complex topic with possibly 
improved body composition and dyslipidemia as a positive force on the one hand and 
impaired glucose tolerance and increased insulin resistance as a negative one on the other. 
Direct effects on vessels and organs, such as the heart, is less clear even if seen in 
acromegalic patients, and few studies have evaluated actual cardiovascular events in 
previously GH-treated patients.  
 
2.5.5 Growth hormone treatment and cancer risks 
The vigilance of a potential risk of developing cancer when treated with GH has accompanied 
this treatment since the beginning, being a potent mitogenic and anti-apoptotic hormone and 
based on studies showing that an increased activity of the GH/IGF-I axis is linked to 
increased cancer risk.238,239,251 The link between GH and breast cancer has in particular been 
demonstrated in both epidemiological and clinical studies in which GH and its downstream 
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signaling molecules affect the different stages of tumor development and progression.252,253 In 
animal studies of spontaneous dwarf rats (Gh dr/dr) which lack GH, administration of the 
cancerogenic substance N-methyl-N-nitrosourea did not induce mammary tumors but in GH-
treated Gh dr/dr-rats tumors developed. Furthermore, after cessation of hormone replacement, 
nearly all developed tumors regressed completely.254 Similar findings have also been 
described regarding prostate cancer development in an animal model of GHR-knockout mice 
(Ghr -/-) crossed with the Tag mouse prone to develop prostatic neoplasias.255  
The increased cancer risk in acromegalic patients previously mentioned (section 2.5.1)  and 
the reports from a small cohort study in the UK that showed increased mortality due to 
colorectal cancer and Hodgkin’s lymphoma in patients previously treated with human 
pituitary-derived GH, have further spurred the attention of possible links between GH and 
cancer.256 However, large post-marketing surveillance studies have not detected an increased 
risk in new primary cancers but raised risks of secondary malignancies in children treated 
with rhGH have been seen, which now also is listed in the U.S. labeling of all rhGH 
products.227    
Despite the concerns of a possible carcinogenic effect of GH, long-term studies, properly 
powered to answer this question, are lacking. If GH treatment would have an effect on cancer 
development, one would expect this to occur after an extended time interval since cancer 
development generally includes a series of unfortunate events in the malignifying cell over 
time. Thus, long-term follow-up as well as large cohorts are needed to address this question. 
The SAGhE collaboration is an attempt to achieve this and the last project of this thesis 
covers the long-term cancer risk of GH treatment in childhood. 
 
2.5.6 Concluding remarks regarding the safety of childhood growth 
hormone treatment 
The issue of long-term safety of GH treatment in childhood is important to large groups of 
treated patients worldwide. Both biological and epidemiological studies warrant a concern for 
certain types of risks with this treatment, but addressing this issue is challenging for several 
reasons mentioned above. While large post-marketing studies have been reassuring regarding 
the short-term safety they also carry with them many limitations and there is still great 
uncertainty regarding the long-term safety of childhood GH treatment. This was the main 
motivating factor for the long-term studies regarding future cardiovascular and cancer risks 
included in this thesis with an attempt to address some of the methodological problems of 
earlier studies in order to bring more clarity to these important questions. 
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3 AIMS 
The overall aim of this thesis was to analyze the metabolic effects and long-term safety of 
recombinant human growth hormone (rhGH) treatment during childhood. In order to 
achieve this aim, the different projects cover a clinical trial with in-depth focus on 
metabolic effects of GH as well as large population-based cohort studies with focus on the 
long-term cardiovascular and cancer risks in childhood rhGH-treated patients.  
The specific aims of the different projects were to:  
 
Study I: 
 Analyze if there are metabolic differences between short prepubertal individuals with 
stimulated GH peak levels in the lower normal range (7-14 µg/L) and healthy age- and 
sex-matched controls of normal height and weight. 
 
Study II: 
 Analyze how treatment with different doses of GH affects different metabolic 
parameters in the short prepubertal children of study I. 
 
Study III: 
 Analyze if patients being treated with rhGH during childhood due to GHD, SGA or ISS 
have an increased risk of cardiovascular morbidity and mortality compared to a 
randomly selected and matched comparison group from the general population. 
 
Study IV: 
 Analyze the risk of cancer morbidity and mortality in patients treated with rhGH during 
childhood compared to the general population. 
 
  
 
 
 
  
 28 
4 METHODS 
The methodology of the different studies included in this thesis will briefly be summarized in 
the following section. A more detailed description can be found in each separate article. The 
first two studies will be described jointly, being part of the same clinical trial, and study III 
and IV will be described separately.  
 
4.1 STUDY POPULATION AND STUDY DESIGN 
4.1.1 Study I and II 
4.1.1.1 Study design and setting 
The first study of this thesis consisted of two parts; a baseline comparison between short 
prepubertal children with GH secretion in the lower normal range and a control group of 
healthy sex- and age-matched children of normal height and weight (Study I) and a 
randomized double-blinded two-year clinical trial of three different doses of rhGH treatment 
in the short children (Study II).  
The study was an open multi-center study with four participating pediatric departments in 
Sweden, with the majority of included short children (32/35) from the Karolinska University 
Hospital in Stockholm. All investigations and in- and outpatient visits were performed at the 
Karolinska University Hospital in Stockholm. For the treatment study, the patients were 
randomized to three different doses of rhGH treatment; low (11 µg/kg/d), standard (33 
µg/kg/d) or high (100 µg/kg/d) dose. The randomization was carried out by the pharmacy at 
the Karolinska University Hospital by a computerized sex-stratified block randomization to 
ensure a balanced allocation to each treatment arm and the double-blinded design.  
 
4.1.1.2 Overview of Study I and II 
A more extensive in-patient examination of different metabolic parameters was carried out at 
0, 12 and 24 months and the visits at 1, 2, 3, 6, 9, 15, 18 and 21 months were regular out-
patient visits with auxological measurements and blood samples. An overview of the two 
studies and the follow-up visits is presented below. 
  29 
 
 
Figure 10. Schematic overview of study I and II 
 
4.1.1.3 Study population  
The study population consisted of 35 short children and 12 controls of normal height and 
weight with the following inclusion and exclusion criteria: 
Inclusion criteria: 
 Age: 7.0-9.9 years 
 Height: <-2.5 SDS (according to the Swedish growth reference257)  
 Normal sitting height (±2 SDS, according to Gerver et al258) 
 Term and normal birth weight for gestational age (±2 SDS according to Swedish birth 
reference259) 
 Bone age <8.5 years in girls and <10 years in boys (assessed by RUS/TW2 – 
radius/ulna/short bones by Tanner-Whitehouse 2nd edition) 
 Normal karyotype (girls) 
 Prepubertal status (Tanner stage: B1, PH1 in girls and G1, PH1 in boys as well as 
testicle volume <4 ml) 
 GH peak value of 7-14 µg/L in an arginine and insulin tolerance test (AITT)  
Exclusion criteria: 
 Any syndrome or recognized disease that could compromise height 
 Any ongoing medical treatment (except for well-controlled hypothyroidism) 
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The control children had to be healthy without any chronic disease or medication and of 
normal height and weight (±1 SDS according to the Swedish growth reference). 
 
4.1.1.4 Blood samples and metabolic examinations 
The investigations included blood samples of fasting insulin, fasting glucose, HbA1c, and 
IGF-I. Calculated values of insulin resistance using the homeostasis model assessment 
(HOMA-IR) was used both by traditional calculation ([f-insulin x f-glucose]/22.5)260 and 
through the up-dated computerized calculator (HOMA2-IR)261. The HOMA-indices have 
been shown to correlate well to the hyperinsulinemic-euglycemic clamp method, considered 
the gold standard of measuring insulin sensitivity.262 
At the in-patient examination, calculation of insulin sensitivity measurements by frequently 
sampled intravenous glucose tolerance test (FSIVGTT), body composition examination by 
dual-energy x-ray absorptiometry (DEXA), analysis of markers of lipolysis in subcutaneous 
adipose tissue by microdialysis and whole body glucose production and lipolysis using stable 
isotope-labeled glucose and glycerol was performed. This in-depth characterization of the 
subjects’ metabolic profiles, with focus on the carbohydrate and lipid metabolism, was the 
major methodological contribution to the research field of study I and II. 
 
4.1.2 Study III 
4.1.2.1 Study design and study population 
Study III was a population-based nation-wide cohort study of cardiovascular events in all 
Swedish rhGH-treated patients from the introduction of recombinant human GH in 1985 to 
the end of 2010. The rhGH-treated patients and their exposure data were collected from the 
Swedish National GH Registry for Children and clinical rhGH-trials during the same period, 
forming the joint GH-SAFETY cohort as described previously.237  
A total of 6,804 patients were identified and for each patient 15 controls, matched on sex, 
birth year and county of residence, were randomly selected by Statistics Sweden (SCB) from 
the Swedish Total Population Register. Information regarding the parents of the patients and 
controls was also gathered from the Multi-Generation Register, creating a complete dataset of 
over 320,000 individuals.  
After exclusion of individuals with previous severe diseases or syndromes, the final study 
population consisted of 3,408 patients and 50,036 controls. Examples of severe diagnoses, 
leading to exclusion, were previous malignant neoplasms, certain benign tumors and 
hematological diseases, endocrine disorders such as diabetes mellitus, congenital syndromic 
and metabolic disorders, chronic inflammatory diseases such as Crohn’s disease, ulcerative 
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colitis, juvenile rheumatic arthritis, chronic renal diseases, chromosomal anomalies, and more 
(see Supplementary Appendix Table S1 of paper III for a complete list).  
A summarized flowchart of the study inclusion and exclusion is presented below: 
 
 
Figure 11. Flowchart of study inclusion and exclusion in study III 
4.1.2.2 Study outcomes and independent variables 
The primary outcome of the study was the first cardiovascular event after the start of the 
follow-up, which equaled the starting date of rhGH treatment in the patient group and the 
corresponding age for the matched controls. The secondary outcome was to investigate the 
first occurrence of only severe cardiovascular events, which included aneurysms, ischemic 
heart disease, cardiomyopathy, heart failure and cerebrovascular disease.  
Outcome data were obtained from the Swedish National Patient Register and from the Cause 
of Death Register. A cardiovascular event was defined according to the ICD codes of the 8th-
10th revision of the International Classification of Diseases. A complete list of ICD codes 
used to define the outcome is presented in the Supplement Appendix (Tables S2) of paper III. 
Data on several potential confounding factors were additionally collected from different 
health- and population-based registries in order to adjust the analyses for these covariates.  
No earlier study on long-term safety of rhGH treatment has to this extent included 
information on possible confounders, such as birth characteristics and socioeconomic status. 
The additional gathering of height data for the control group, from many different available 
sources, furthermore enabled us to adjust our analyses for height, that could be a proxy for 
many underlying factors connected to the risk for the outcome. By adjusting for both birth 
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characteristics, socioeconomic status and height and matching controls on sex, age and 
geographical county, we thus tried, as far as possible, to isolate the effect of earlier rhGH 
treatment on the studied outcomes. 
 
Table 2. Summary of all variables and their sources in study III 
Category Variable Source 
Outcome Cardiovascular events  The Swedish National Patient Register 
 Cardiovascular death The Swedish Cause of Death Register  
Exposure Treatment indication 
Treatment duration 
Mean rhGH-dose 
Cumulative rhGH-dose 
The Swedish National GH Registry for 
Children and clinical rhGH-trials 
 Adult rhGH treatment The Swedish Prescribed Drug Register 
Birth characteristics 
 
Gestational age 
Birth weight 
Birth length 
The Swedish Medical Birth Register 
Socioeconomic status Parental educational level The Swedish Register of Education 
 Family income level The Swedish Income and Taxation Register 
Individual factors Random selection of matched 
controls 
The Swedish Total Population Register  
 Link parent-child Multi-Generation Register 
 Height of patients at study start The Swedish National GH Registry for 
Children and clinical rhGH-trials 
 Height of controls at study start* The Swedish Passport Register 
  The Swedish Military Conscription Register 
  The Swedish Medical Birth Register 
* Height data for the controls were gathered from several sources and height at study start was estimated using a mixed-
effects model from all height measurements (for details, see Supplementary Appendix of paper III). 
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4.1.3 Study IV 
4.1.3.1 Study design and study population 
Paper IV of the thesis is part of a joint collaboration between eight European countries, the 
Safety and Appropriateness of Growth Hormone Treatments in Europe (SAGhE) study, in 
which a large meta-cohort of rhGH-treated children has been assembled to evaluate its long-
term effects and safety. This study addresses the issue of cancer risk in previously rhGH-
treated patients. 
The eight participating countries in the 
SAGhE study are France, Belgium, The 
Netherlands, Germany, Italy, Switzerland, 
the United Kingdom and Sweden.  
A total of approximately 24,000 patients 
were included for the cancer mortality 
analyses with almost 400,000 person-years 
of follow-up. For cancer incidence 
analyses, only the countries with a national 
cancer registration with high coverage rate 
was included (Belgium, The Netherlands, 
Sweden, Switzerland and the United 
Kingdom) and for the other countries only 
numbers of cancer were reported.  
Figure 12. The participating countries in the SAGhE study  
 
4.1.3.2 Risk group stratification, study outcomes and independent variables 
Since the initial diagnosis leading to rhGH treatment is expected to be highly related to the 
outcome, all analyses were stratified based on a risk group classification connected to the 
underlying treatment indication.232 In addition, certain diagnoses leading to rhGH treatment 
in which cancer risks are greatly increased, such as Type 1 neurofibromatosis, 
retinoblastoma, solid organ transplantation, and chromosomal syndromes (e.g. Fanconi or 
Bloom syndrome), were excluded. The risk group classification of a high, intermediate and 
low risk group corresponded largely to the arrangement of the patients into three overall 
groups; patients with an initial cancer diagnosis, a non-cancer diagnosis or only isolated 
growth failure (isolated GHD, ISS or SGA). All classification and exclusion were performed 
prior to any collection of outcome data or analysis.  
The cancer mortality and incidence data were gathered from national population-based 
registries in Belgium, The Netherlands, Sweden and the United Kingdom, and by a multitude 
of sources, such as region-specific cancer registries, questionnaires, hospital discharge and 
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insurance records, for the other four countries.232 Demographic and exposure data were 
mainly gathered from national population registries and from national population-based 
clinical treatment registries.  
Several challenges are unavoidable when creating large meta-cohorts from several countries 
with different included sources and this complexity in the data needs to be considered when 
analyzing the aggregated data. Creating a large cohort from several countries was, on the 
other hand, necessary to reach sufficient statistical power when analyzing such rare events as 
cancer incidence and mortality in young adults. Country-specific analyses were also 
performed to assess the degree of national differences between the included countries. By the 
joint effort of the SAGhE consortium, the largest cohort of rhGH-treated children with the 
longest follow-up for cancer incidence and mortality was created, making it a very important 
contribution to the long-term surveillance of previously rhGH-treated children.  
 
4.1.4 Statistical analyses 
4.1.4.1 Study I and II 
For the baseline comparison of the short children and the sex- and age-matched controls 
(Study I) the main statistical test was a two-sample independent t-test for approximately 
normally distributed variables and Wilcoxon rank-sum test for non-normally distributed 
variables. Similarly, correlation analyses were performed with Pearson product-moment 
correlation (r) for approximately normally distributed variables and Spearman’s rank 
correlation coefficient (rs) for non-normally distributed variables. In the subgroup analyses of 
multiple groups, either ANOVA or Kruskal-Wallis test was used. The subgroups of patients 
were defined by a GH peak level above or below 10 µg/L. Post-hoc analyses were performed 
with Tukey’s honestly significant difference for parametric data and Dunn’s test for non-
parametric data.  
For the treatment study (Study II) the main statistical method was a mixed-effects model to 
account for the dependence in the data due to repeated measures at different time points of 
each individual and to more efficiently handle missing values in a series of measurements 
compared with other methods, such as for example a repeated-measures ANOVA. A mixed-
effects model can be seen as a hierarchical model where the data are clustered on different 
levels, both on an individual level and on a higher level of different treatment groups. The 
name mixed-effects derives from the combination of both a fixed effect (treatment 
assignment) and a random effect (individual variation within each treatment group).  
 
4.1.4.2 Study III 
In study III, the main objective was to analyze time from start of the study (treatment start or 
corresponding age for the matched controls) to the first recorded cardiovascular event. The 
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most commonly used statistical method for time-to-event analysis, or survival analysis as it is 
also called, is the Cox proportional-hazard regression model, and this was also the method 
used for this study.  
The Cox model estimates the hazard function or hazard rate, i.e. the risk of an event 
(“failure”) to happen at a certain point in time per time unit. When comparing hazard rates in 
different groups we calculate a ratio between the rates, the hazard ratio (HR). In our study of 
comparing the hazard rates for patient versus controls, a HR greater than 1 means that the risk 
of an event during the specified time interval is greater in the patients (exposed group) than in 
the controls (non-exposed group). If less than 1, the hazard is higher in the controls, and if 
equal to 1, the hazard rates are equal between the two compared groups. The estimations can 
be adjusted for multiple covariates making it possible to better isolate the effects of rhGH 
treatment when analyzing the association of treatment exposure and cardiovascular outcomes. 
Two different adjusted models were used in our study apart from presenting crude HRs; a 
restricted model only including sex, age and height at study start, and a full model, which in 
addition included gestational age, birth length, birth weight, socioeconomic status (parental 
education and income quintile). Thus, the full model represents the estimated HR that fully 
takes all these potential confounders into consideration. The Cox model is based on a 
proportional-hazard assumption. We tested it by Schoenfeld’s residuals and visual inspection 
of the estimated hazard functions and found no evidence against it. 
Analyses of subgroups of patients, categories of treatment exposure (treatment duration, 
mean and cumulative dose) and a sensitivity analysis on a subset of patients and controls 
more similar in height and birth characteristics at study start were also performed. The dose-
response analyses were performed with a lag-period of two years since the end of treatment to 
avoid the risk of reversed causality (protopathic bias) due to the potential association of 
treatment termination and the outcome or early manifestations of the outcome. 
For the estimation of height at study start in the controls, a mixed-effects model based on 
multiple height measurements of each control was used. The estimated value was the best 
linear unbiased predictor from the model and the analysis was done only in the control 
children and separately by sex. Due to non-linearity of the relationship between mean height 
and age over time, age was introduced in the model by means of natural cubic splines. The 
determination of the number and placement of the spline knots were done in order to 
maximize the goodness of fit as measured by the likelihood and also evaluated through 
graphical representation. 
Crude incidence rates of cardiovascular events during the follow-up time with 95% 
confidence intervals (CIs) were also calculated for each subgroup of explanatory variables 
and presented as events per 10,000 person-years. Finally, Fisher’s exact test was used to 
analyze different proportions of events within each subcategory of cardiovascular ICD-codes.  
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4.1.4.3 Study IV 
The main statistical analysis to evaluate cancer mortality and incidence risks in study IV was 
calculation of standardized mortality ratios (SMRs), standardized incidence ratios (SIRs), and 
trends of SMRs/SIRs over categorical variables (p-trends). A SMR or SIR is a ratio between 
the observed number of cancer deaths or cancer incident cases in a certain study population 
and the expected numbers based on age- and sex-specific rates in the reference population.  
 
𝑆𝑀𝑅/𝑆𝐼𝑅 =
Observed number of deaths/incident cases
Expected number of deaths/incident cases
 
 
Person-years at risk for cancer mortality were calculated for each patient by sex, calendar-
year, 5-year age group and country, from date of first rhGH treatment to whichever occurred 
first: death, loss of follow-up, or a fixed censoring date (separate for each country). For 
cancer incidence, the same method was used but also adding the date of cancer diagnosis as 
an additional failure event. In analogy to HRs, an SMR or SIR over 1 means that the 
observed numbers exceeds the expected numbers, indicating an increased risk in the study 
population compared with the reference population. Absolute excess risks (AERs) were 
calculated by subtracting the expected from the observed number of cases, divided by the 
person-years at risk and multiplying by 10,000. 
 
4.1.5 Ethical approvals 
All studies in this thesis have been approved by the Regional Ethics Review Board in 
Stockholm (Dnr: 01-069, 2010/578-31/1, 2011/109-32-1, 2011/305-32 and 2014/1775-32)  
and the clinical study (study I and II) was conducted in accordance with the ethical principles 
of the Declaration of Helsinki.263 
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5 RESULTS 
5.1 STUDY I AND II 
5.1.1 Comparison of metabolic parameters at baseline (Study I) 
5.1.1.1 Metabolic differences between short children and controls 
In the overall comparison of the short children with GH peak levels in the lower normal range 
(GHmax 7-14 µg/L) and the controls of normal height and weight, no significant differences in 
the investigated metabolic parameters were seen. Some tendencies could however be noted, 
where the patient group in comparison with the controls had lower fasting insulin (20.8 vs 
28.8 pmol/L, p = 0.07), IGF-I (83 vs 103 µg/L, p = 0.09), HOMA indices (HOMA-IR; 0.75 
vs 1.00 p = 0.09, HOMA2-IR; 0.40 vs 0.55, p = 0.06) and total fat mass (16.2 vs 19.6 %, p = 
0.07). No clear differences or tendencies were seen for the FSIVGTT, microdialysis or 
isotopic examinations.  
5.1.1.2 Subgroup analyses based on GH peak levels above or below 10 µg/L 
When dividing the patients into two subgroups based on their GH peak levels, using a 
common and “classical” cut-off for defining GHD or ISS (above or below 10 μg/L), several 
significant metabolic differences between the groups were seen. The three groups differed 
most clearly in measurements of IGF-I, fasting insulin and the HOMA indices. Post-hoc 
analyses showed that the subgroup of patients with the lowest GH peak levels (GHmax < 10 
µg/L) differed both from the patients with higher GH peak levels (GHmax > 10 µg/L) and the 
controls. However, the subgroup of patients with GHmax >10 µg/L did not differ in these 
parameters or any other (except HbA1c) from the control children.  
The comprehensive result table is found in paper I (table 3) and a selection of variables from 
the subgroup analyses, with p-values for the post-hoc analyses, is presented below: 
 
Figure 13. Comparison of IGF-I and fasting insulin between the different groups 
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Figure 14. Comparison of HOMA-IR and HOMA2-IR between the different groups 
 
The subgroups of patients did not differ at all regarding body composition (p = 1.00 on all 
three variables; abdominal fat mass, total fat mass and lean body mass). Neither did any of 
the subgroups differ significantly in body composition compared to the controls. Moreover, 
no differences were seen regarding FSIVGTT, microdialysis or the stable isotope 
examinations in the subgroup analyses. 
 
5.1.2 Metabolic effects of different rhGH-doses (Study II) 
5.1.2.1 Enrollment and completion of the treatment study 
A total of 37 short prepubertal children were enrolled in the study with two participants 
excluded at a later stage due to being small for gestational age when recalculating their birth 
data. Of the 35 children that were randomized to the three different doses of GH, 31 
completed the full two-year study and all follow-up examinations. Four children terminated 
the study before 24 months; three in the low dose group and one in the high dose group.  
A flow chart of the study inclusion, reasons for exclusion or study termination and follow-up 
information is presented below. 
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Figure 15. Flow chart of study inclusion, exclusion and follow-up in Study II 
 
5.1.2.2 Metabolic differences between the three treatment groups at 12 and 24 months 
At 12 months, differences between the treatment groups were seen regarding IGF-I, body 
composition, HOMA indices, and the FSIVGTT, in which particularly the high dose group 
had higher IGF-I levels, less total fat mass and decreased signs of insulin sensitivity. The 
standard dose group also showed lower insulin sensitivity (Si) in the FSIVGTT compared to 
the low dose group.  
At the end of the study (24 months), similar differences as seen at 12 months were found, 
with the high dose group most clearly separated from the low and standard dose groups. In 
addition to the effects seen on HOMA indices earlier, the high dose group now also showed 
significantly higher fasting insulin levels and had over the study period a significant increase 
in fasting glucose (+0.6 mmol/l, p=0.004) and HbA1c (+1.4 mmol/mol, p=0.046).  
The major differences in the metabolic outcomes are summarized below in table 3 and 
differences over time for a selection of variables in figure 16.  
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Table 3. Comparison of metabolic outcomes at 12 and 24 months  
Note: Mean (SD). IGF-I = insulin-like growth factor I, HOMA-IR/HOMA2-IR = homeostasis model assessment of insulin resistance, Si = 
(insulin) sensitivity index (measured by frequently sampled intravenous glucose tolerance test), AIR = acute insulin response (measured by 
frequently sampled intravenous glucose tolerance test), N.S. = non-significant.  
 
5.1.2.3 Auxological and metabolic changes over the study period 
Several auxological and metabolic changes did also occur over the study period within each 
treatment group. Changes from the start of the study to the end at 24 months of follow-up 
(delta [Δ] values, 0-24 months) showed a clear difference in both absolute values and within-
group variation in Δ-values between the groups.  
The standard and high dose groups had both larger Δ-values for height SDS, fasting insulin, 
HOMA-IR, as well as larger variation compared to the low dose group. In all the groups 
height SDS and weight SDS increased but most distinctly in the high and standard dose 
group. Effects on fasting insulin and HOMA-IR were most noticeable in the high dose group 
as well as the reduction of total body fat measured by DEXA. The Δ-values for a selection of 
variables are presented below in figure 16. 
 
    p-values 
 Low dose 
(11µg/kg/d) 
Standard dose 
(33µg/kg/d) 
High dose 
(100µg/kg/d) 
Low vs 
Standard 
Standard 
vs High 
Low vs 
High 
12 months 
      
F-insulin (pmol/L) 52.5 (36.4) 43.5 (26.4) 74.7 (36.9) N.S. N.S. N.S. 
IGF-I (µg/L) 197 (98) 242 (62) 352 (121) N.S. <0.001 <0.001 
HOMA-IR 1.99 (1.61) 1.51 (0.95) 2.77 (1.48) N.S. 0.006 N.S. 
HOMA2-IR 1.00 (0.70) 0.83 (0.49) 1.43 (0.72) N.S. 0.012 N.S. 
Si ([mU/l]-1 x min-1) 10.1 (2.5) 6.4 (1.7) 5.4 (1.8) 0.025 N.S. 0.003 
AIR (mUxL-1 x min) 271 (203) 395 (300) 509 (264) N.S. N.S. 0.026 
Tot. fat mass (%) 16.9 (6.2) 14.2 (6.1) 11.0 (4.8) N.S. N.S. 0.035 
       
24 months       
F-insulin (pmol/L) 46.0 (22.9) 61.2 (35.8) 111.7 (52.9) N.S. <0.001 <0.001 
IGF-I (µg/L) 220 (106) 291 (105) 402 (114) 0.007 0.002 <0.001 
HOMA-IR 1.71 (0.93) 2.17 (1.38) 4.20 (1.94) N.S. <0.001 <0.001 
HOMA2-IR 0.89 (0.44) 1.17 (0.69) 2.13 (0.96) N.S. <0.001 <0.001 
Si ([mU/l]-1 x min-1) 7.9 (2.0) 7.8 (2.9) 5.2 (2.5) N.S. N.S. N.S. 
AIR (mUxL-1 x min) 348 (229) 418 (337) 667 (388) N.S. 0.035 0.009 
Total fat mass (%) 17.2 (9.6) 15.8 (6.3) 12.9 (6.3) N.S. N.S. N.S. 
  41 
 
Figure 16. Changes in auxological and metabolic outcomes over the study period 
The box-plots (a-f) show changes from baseline to the end of the study period (Δ-values, 0-24 months) for the three treatment 
groups in different auxological and metabolic parameters.  
 
5.2 STUDY III 
5.2.1 Childhood rhGH treatment and long-term cardiovascular morbidity 
5.2.1.1 Characteristics of the study cohort and crude incidence rates of cardiovascular 
events 
The final study population included 3,408 patients and 50,036 controls matched on age, sex 
and geographical region, with a total follow-up time of almost 800,000 person-years (pyrs). 
The mean follow-up time was 14.9 years and the mean age at study end was 25.1 years.  
A total of 1,809 cardiovascular events were recorded during the follow-up, of which 167 
were categorized as severe events. The crude incidence rates of a cardiovascular event were 
25.7 events/10,000 pyrs among the patients and 22.6 events/10,000 pyrs among the controls. 
The rate was higher in female patients (31.2 events/10,000 pyrs) than in female controls (23.2 
events/10,000 pyrs) but similar among male patients and controls (23.3 vs 22.3 events/10,000 
pyrs). For the first severe cardiovascular event, the crude incidence rate was 3.48 
events/10,000 pyrs in patients and 1.97 events/10,000 pyrs in controls. 
 
5.2.1.2 Risk of overall and severe cardiovascular events 
The main analysis of comparing time to the first overall cardiovascular event between the 
patient and the control group, showed a crude HR of 1.13 (95% CI: 0.95-1.36), which 
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increased in the restricted model (HR 1.58, 95% CI: 1.23-2.01) and furthermore in the fully 
adjusted model (HR 1.69, 95% CI: 1.30-2.19). This increased hazard was most clearly seen in 
the female patients (HR 2.05, 95% CI: 1.31-3.20). In the subgroup of patients, the increased 
HR was most evident in the SGA group (HR 1.97, 95% CI: 1.28-3.04) but also seen in GHD, 
defined as stimulated GH levels <10 µg/L, (HR 1.66, 95% CI: 1.21-2.26) and ISS (HR: 1.55, 
95% CI: 1.01-2.37). For the subgroups of GHD patients (with stimulated GH levels of 0-4 
μg/L and 5-9 μg/L) the HRs were 1.79 (95% CI: 1.12-2.87) and 1.60 (95% CI: 1.12-2.28), 
respectively.  
For the first severe cardiovascular event, the crude HR was 1.75 (95% CI: 1.08-2.87) and also 
increased in the adjusted models (restricted model: HR 1.56, 95% CI: 0.73-3.34 and full 
model: HR 2.27, 95% CI: 1.01-5.12, respectively). The sensitivity analysis, only keeping 
controls more similar in height and birth characteristics at study start, demonstrated similar 
results as our overall analyses for both overall and severe cardiovascular events (see 
Supplement Appendix of paper III for details).  
A forest plot of the different HRs in the main subgroups of patients is presented below for 
overall and severe cardiovascular events. A full list of all HRs for first overall and severe 
cardiovascular event is found in the tables 3 and 4 of paper III.  
 
 
Figure 17. Forest plot of adjusted hazard ratios for first overall and severe cardiovascular event 
The hazard ratios were adjusted for gestational age, birth length, birth weight, age at start, height at start, parental educational 
level, family income and sex (if not stratified for sex). HR = Hazard ratio, SGA = Small for gestational age, GHD = Growth 
hormone deficiency, GHmax = Growth hormone peak level, ISS = Idiopathic short stature, CVD = cardiovascular disease. 
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5.2.1.3 Dose-response analyses 
To further investigate any association with dose or duration, analyses by different categories 
of treatment duration, mean and cumulative dose were performed. The highest HRs were 
seen in the longest duration category (≥7 years); 2.08 (95% CI: 1.35-3.20) and the highest 
cumulative dose category (≥4,500 mg); 2.05 (95% CI: 1.18-3.55) with a significant 
increasing trend over the duration categories (p = 0.01) but not over the cumulative dose 
categories (p = 0.24). No association with higher mean dose and increased HR was seen.  
 
Table 4. Dose-response analyses for overall cardiovascular events 
 
* Adjusted for gestational age, birth length, birth weight, age at start, height at start, parental educational level, family 
income and sex. 
 
 
5.3 STUDY IV 
5.3.1 Cancer risks after childhood rhGH treatment 
5.3.1.1 Characteristics of the study cohort and number of incident cancer cases and 
deaths 
For the cancer mortality analyses, patients from all eight countries were included, totaling 
almost 400,000 patient-years, with an average of 16.5 years of follow-up per patient. For the 
cancer incidence analyses, only patients from Belgium, The Netherlands, Sweden, 
Switzerland and the United Kingdom were included, comprising a total of 154,371 patient-
 
N Adjusted* HRs [95% CI] p-value 
Duration of treatment 
   
0-2 years 925 1.05 [0.59-1.88] 0.87 
3-6 years 1,522 1.58 [1.10-2.28] 0.01 
≥7 years 961 2.08 [1.35-3.20] <0.01 
P trend  0.01  
    
Mean GH-dose    
0-29 µg/kg/d 402 1.76 [0.82-3.77] 0.15 
30-39  µg/kg/d 2,383 1.64 [1.18-2.28] <0.01 
40-49  µg/kg/d 337 1.25 [0.60-2.59] 0.55 
≥50  µg/kg/d 279 1.51 [0.79-2.91] 0.22 
P trend  0.51  
    
Cumulative dose    
0-1,499 mg 1,015 1.34 [0.80-2.25] 0.26 
1,500-2,999 mg 954 1.76 [1.16-2.68] <0.01 
3,000-4,499 902 1.36 [0.84-2.18] 0.21 
≥4,500 mg 381 2.05 [1.18-3.55] 0.01 
P trend  0.24  
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years, with an average of 14.8 years per patient. A total of 251 cancer deaths and 138 incident 
cancer cases were recorded during the follow-up period. 
5.3.1.2 Cancer mortality by underlying diagnosis 
Overall cancer mortality was to a very large extent related to the underlying diagnosis leading 
to GH treatment. Patients treated with GH due to an initial cancer diagnosis had, as expected, 
a highly increased SMR for overall cancer mortality (SMR: 101.9, 95% CI: 89.6-116.0), 
especially for CNS tumors (SMR: 373.4, 95% CI: 318.6-437.5) and leukemia (SMR 45.5, 
95% CI: 30.2-68.5), which contributed with 153 and 23, respectively, of the total of 230 
cancer deaths. These specific cancer types were followed by bone tumors (n=8) and soft 
tissue tumors (n=5), which had SMRs of 35.5 (95% CI: 17.7-70.9) and 47.2 (95% CI: 19.7-
113.4), respectively.  
The remaining patients, with an initial non-cancer diagnosis, were further divided into 
patients with isolated growth failure (GHD, ISS or SGA), which contributed to more than 
half of the total cohort, and other non-cancer diagnoses (such as multiple pituitary hormone 
deficiency, Turner syndrome, and skeletal dysplasias). For isolated growth failure patients, 
the overall risk was not increased (SMR 0.8, 95% CI: 0.4-1.6) but the site-specific mortality 
for bone tumors was increased (SMR 3.1, 95% CI: 1.0-9.6). For other non-cancer diagnoses 
the overall cancer mortality risk was increased (SMR 2.2, 95% CI: 1.3-3.7) but no particular 
site-specific increased SMR was seen.  
 
5.3.1.3 Cancer incidence by underlying diagnosis 
As for cancer mortality, cancer incidence risk was highly influenced by underlying diagnosis. 
The overall SIR for those with an initial cancer diagnosis was 7.6 (95% CI: 6.1-9.6) and the 
most common location for a second primary malignancy was the central nervous system 
(n=23, SIR: 34.7, 95% CI: 23.1-52.2) followed by the thyroid gland (n=10, SIR: 32.2, 95% 
CI: 17.3-59.8), skin melanoma (n=5, SIR: 5.8, 95% CI: 2.4-13.9) and bone tumors (n=5, SIR: 
17.2, 95% CI: 7.2-41.4).  
For non-cancer diagnoses, overall SIR was 1.0 (95% CI: 0.6-1.4) in the isolated growth 
failure group, and 1.4 (95% CI: 1.1-1.9) for the other non-cancer diagnoses.  No site-specific 
increased SIR was seen in the isolated growth failure patients but for the other non-cancer 
diagnoses, both bone (SIR: 4.1, 95% CI: 1.3-12.6) and bladder (SIR: 27.8, 95% CI: 7.0-
111.3) malignancies were significantly increased, however based on few cases (3 and 2, 
respectively).  
Both cancer mortality and incidence risks are summarized in table 5 below. 
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Table 5. Cancer mortality and incidence by underlying diagnosis 
 
5.3.1.4 Cancer mortality and incidence by demographic and treatment variables 
In the comparison between males and females, similar SIRs were seen for both patients with 
an initial cancer diagnosis (M: 7.2, 95% CI: 5.0-10.3; F: 8.0, 95% CI: 5.9-10.8) and for those 
with an initial non-cancer diagnosis (M: 1.1, 95% CI: 0.7-1.7; F: 1.3, 95% CI: 1.0-1.7). In 
contrast, females had higher SMRs for both those with an initial cancer diagnosis (M: 90.2, 
95% CI: 76.0-107.0; F: 123.1, 95% CI: 101.1-149.9) and those with an initial non-cancer 
diagnosis (M: 0.7, 95% CI: 0.3-1.5; F: 2.2, 95% CI: 1.3-3.7). 
When analyzing time since start of treatment, overall diminishing risk for cancer mortality (p 
< 0.001) but not cancer incidence (p = 0.13) was seen in the total cohort with shorter duration 
since treatment cessation (with similar trends regarding treatment duration and cumulative 
GH dose). However, a time-lag analysis, censoring the first two years after the end of 
treatment, greatly diminished the association between higher SMR and shorter treatment 
duration, suggesting a possible reversed causality of treatment cessation due to cancer 
recurrence rather than cancer recurrence due to short treatment duration.  
In patients with isolated growth failure, significant trends for higher cancer incidence were 
seen for increasing time since start of treatment (p = 0.02) and duration of treatment (p = 
0.02) but not clearly for cumulative dose (p = 0.08) and not at all for mean dose (p = 0.52) or 
cancer mortality. In patients with an initial cancer diagnosis, a higher mean daily GH dose 
was associated with an overall higher SMR (p < 0.001) but not higher SIR (p = 0.59).  
Analysis of site-specific cancer risks found diminishing risk of CNS tumor mortality in the 
initial cancer diagnosis group with longer-follow up (p < 0.001) and increasing incidence of 
Hodgkin’s lymphoma in initial non-cancer patients (p = 0.002). No other clear trends were 
 
N SMR / SIR [95% CI] p-value 
Cancer mortality    
All initial diagnoses 251 13.7 [12.1-15.5] <0.001 
Initial cancer diagnosis 230 101.9 [89.6-116.0] <0.001 
Initial non-cancer diagnosis 21 1.3 [0.9-2.0] N.S. 
- Isolated growth failure (GHD, ISS, SGA) 8 0.8 [0.4-1.6] N.S. 
- Other non-cancer diagnoses 13 2.2 [1.3-3.7] <0.05 
    
Cancer incidence    
All initial diagnoses 138 2.2 [1.9-2.6] <0.001 
Initial cancer diagnosis 72 7.6 [6.1-9.6] <0.001 
Initial non-cancer diagnosis 66 1.2 [1.0-1.6] N.S. 
- Isolated growth failure  23 1.0 [0.6-1.4] N.S. 
- Other non-cancer diagnoses 42 1.4 [1.1-1.9] <0.05 
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seen regarding duration since treatment start and site-specific cancer mortality or incidence 
risks.    
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6 DISCUSSION 
 
6.1 METABOLIC EFFECTS OF GH TREATMENT (STUDY I AND II) 
In the first two studies, several metabolic effects connected to GH physiology were seen. One 
of the most noticeable findings was the strong association between GH and the effects on 
carbohydrate metabolism and especially on insulin sensitivity. This association was seen both 
in the comparison of short children with stimulated GH peak levels in the lower normal range 
and controls of normal height and weight (Study I) and in the assessment of various GH 
doses (Study II).  
 
Metabolic features of short prepubertal children 
In study I, differences between subgroups of patients (below or above GHmax of 10 µg/L) 
were seen, indicating different metabolic phenotypes in the short children within the range of 
included GH peak levels. The subgroup of patients with GHmax <10 µg/L showed lower 
IGF-I, fasting insulin and HOMA-IR/HOMA2-IR levels both compared to the controls and 
the short children with GHmax >10 µg/L. However, no metabolic differences (except for 
HbA1c) were seen between the short children with GHmax >10 µg/L and the control children. 
Moreover, no differences were seen in body composition between the subgroups of short 
children, indicating an association between lower fasting insulin and increased insulin 
sensitivity and low GH peak levels independent of differences in body composition. This 
observation is in line with the suggestion of alternative mechanisms on how GH contributes 
to decreased insulin sensitivity, affecting both central (hepatic) and peripheral insulin 
sensitivity discussed in sections 2.3.2.3-4.  
Furthermore, this study also showed that the metabolic phenotype of short children with GH 
peak levels in the lower normal range differ substantially from the phenotype of patients with 
severe GHD, which have increased fat mass (especially abdominal fat mass) and BMI due to 
impaired lipolysis. Possibly, the level of GH secretion in our group of short children was 
sufficient to uphold a normal degree of lipolysis but at a low enough level to create a situation 
of increased insulin sensitivity, contributing to their phenotype of being both slim and short. 
Supporting this idea is also the findings from the stable isotopic examinations demonstrating 
similar levels of whole body glucose production and lipolytic activity between the groups.  
Few earlier studies have investigated the metabolic characteristics of untreated short children 
in this range of stimulated GH peak levels (7-14 µg/L). However, an earlier study on short 
children with different levels of GH secretion have, similar to our results, shown that lower 
GH peak levels were associated with increased insulin sensitivity.159 It was also shown that 
the group with lower GH peak levels had higher BMI, further supporting the notion of 
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mechanisms independent of body composition connected to the characteristics of increased 
insulin sensitivity.  
 
Metabolic effects of different rhGH doses 
In study II, investigating the effect of different rhGH doses, a clear dose-dependent effect on 
fasting insulin levels and indices of insulin sensitivity was seen. Over time, all groups had 
increasing levels of fasting insulin, but the high dose group had significantly higher levels 
compared with both the standard and low dose group. Furthermore, insulin resistance 
measured by HOMA-IR and HOMA2-IR was distinctly increased in the high dose group 
compared to the standard and low dose groups.  
Insulin sensitivity measured by frequently sampled intravenous glucose tolerance test, 
demonstrated decreasing insulin sensitivity in all groups over the study period but occurring 
earlier, already at 12 months, in the high and standard dose group compared to the low dose 
group. Possibly the higher amount of pubertal development in the low dose group could 
have contributed to reduce the difference between the groups at 24 months. Similarly, 
effects on body composition, demonstrating the lipolytic effects of GH, were also most 
clearly seen at 12 months, where the high dose group had lower total fat mass compared to 
the standard and low dose groups. Lastly, the high dose group had the largest increase in 
IGF-I and largest Δ height SDS gain of the groups.  
Similar results to ours have been reported in previous studies, showing increasing levels of 
fasting insulin and decreased insulin sensitivity during GH treatment in prepubertal children 
with or without GHD, but without any major impact on fasting glucose and glucose 
tolerance.160-163,264-266 However, more recent studies on GHD patients have also reported 
effects on fasting glucose both associated with higher GH doses164 and independent of 
dose165-168. In our study, the participants in the high dose group did also have a significant 
effect on fasting glucose and HbA1c and were, compared to recently published267 pediatric 
references data, above the 95th percentile for fasting insulin, glucose and HOMA-IR but not 
HbA1c. The standard and low dose group were, on the other hand, within the normal ranges 
for these analyses even if demonstrating clearly increasing levels of fasting insulin and 
HOMA-IR over the study period.  
 
6.2 CHILDHOOD GH TREATMENT AND LONG-TERM CARDIOVASCULAR 
RISKS (STUDY III) 
Study III, a population-based cohort study of Swedish rhGH-treated children from 1985 to 
2010, showed that rhGH treatment due to GHD, SGA or ISS during childhood was associated 
with increased risk of cardiovascular events later in life. This was seen both for overall and 
severe cardiovascular outcomes, although the absolute risks were relatively low in both 
patients and controls, being rare events in a quite young cohort. The association was most 
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evident in female patients, patients treated due to SGA and in those with the longest duration 
of treatment and the highest cumulative dose. Additional analyses, comparing only patients 
and controls similar in height and birth characteristics at study start, or only those with 
documented treatment in adulthood (>18 years of age) from the Prescribed Drug Register, 
showed similar results as the main analyses. 
The number of previous studies investigating long-term cardiovascular outcomes in rhGH-
treated patients are very limited and most of them have primarily focused on cardiovascular 
mortality and reported unadjusted SMRs in adult-treated patients.268,269 Furthermore, the 
included patients have a large variety of, and often severe, underlying conditions, making it 
difficult to draw definite conclusions regarding the impact of rhGH on the studied outcomes. 
Thus, in order to isolate the effect of rhGH, one must try to control for possible confounders 
and have a comparison group which ideally only differs in treatment exposure. In this study, a 
great deal of effort was put into this task, in order to, as far as possible, handle important 
confounders; such as birth characteristics, socio-economic factors and underlying 
(unmeasured) confounders associated with height and to filter out severe diagnoses in both 
patients and controls.  
The hazard ratio for a cardiovascular event was approximately doubled for females overall 
and for the children treated due to SGA, although with quite wide confidence intervals, 
ranging from a third to a threefold increased risk. Earlier studies have also reported increased 
cardiovascular mortality risks in female versus male rhGH-treated adult patients but the 
underlying reason for this sex difference still remains unclear.268,269 For mortality analyses, 
the low mortality risks in the female background population might explain increased SMRs, 
but this explanation seems insufficient for comparisons of morbidity.  
The association of later cardiovascular diseases in children born SGA is well-known since the 
British epidemiologist David Barker formulated his hypothesis of fetal and infant origins of 
adult disease270, later confirmed by several studies271-273. In particular, rapid postnatal weight 
gain has been found to increase the risk of several cardiovascular outcomes in adult life.274-276 
However, the approved indication of GH treatment in SGA children is restricted to those who 
lack a catch-up growth, at least for height, in their first years of life. In theory, our subgroup 
of SGA children might thus have a lower baseline risk regarding cardiovascular diseases 
compared to other subgroups of SGA children with more rapid post-natal growth. Even so, 
we found a doubled risk of such outcomes when adjusting for birth characteristics, such as 
birth length, birth weight and gestational age. To further investigate this issue, one would 
need information on post-natal growth in both treated and untreated SGA children and 
preferably also identify other differences between the groups to further reduce potential 
residual confounding.  
The argument of adult GH treatment in GHD patients is largely based on the metabolic 
effects of GH and particularly its favorable effects on lipid metabolism and body 
composition. Several studies on adult GH treatment have demonstrated such effects242,243,277 
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but others243-245 have also reported negative effects, with increased insulin resistance and risk 
of type 2 diabetes mellitus, both findings consistent with the physiological effects of GH.  
In our study, a sub-analysis of childhood rhGH-treated patients with treatment continuation 
after 18 years showed quite substantially higher HRs than our main analyses, arguing against 
an overall favorable effect on cardiovascular outcomes in our cohort (see Table S3, 
Supplementary Appendix of paper III for details). However, it is important to note that the 
studies cited above consist predominantly of patients with adult-onset GHD which, compared 
to childhood-onset GHD patients, differ greatly in etiology (mainly intracranial tumors or 
their treatment thereof disturbing the hypothalamic-pituitary axis) and level of deficiency 
(often a complete lack or very low levels of sustained GH secretion). In childhood-onset 
GHD, perhaps the severe forms with clearly deranged body composition and lipid 
metabolism could benefit from adult treatment, since such a phenotype would otherwise 
presumably lead to increased insulin resistance and subsequent cardiovascular morbidity. 
Thus, finding a balance of risk and benefit based on the underlying etiology and level of GH 
deficiency in the individual patient is most likely preferable in comparison to a strict general 
principle regarding adult treatment. 
For severe cardiovascular outcomes, the patient group had approximately a doubled risk 
overall with, similarly as for the main analyses of overall cardiovascular events, higher HRs 
in the females compared to males. However, the absolute risks were even lower than for 
overall cardiovascular events, with few cases and wide confidence intervals. When 
comparing the proportions of specific severe cardiovascular outcomes, the patient group had 
a significantly higher amount of ischemic cardiac disease and cardiomyopathy. The link of 
GH excess and effects on the heart is well-known since cardiomyopathy with biventricular 
hypertrophy of the heart is one of the hallmark cardiac complications seen in acromegalic 
patients.278,279 On the other hand, GHD is also associated with changes in heart morphology 
and function, with decreased cardiac size and cardiac output, opposite to the effects of GH 
excess.279 Thus, avoiding both too high and too low levels of GH seems once again advisory. 
With regards to rhGH treatment, abiding to approved treatment indications and carefully 
monitoring effects of the treatment (IGF-I levels and growth response), is likely to be 
favorable in order to reduce such future cardiac morbidity risks.  
 
6.3 CHILDHOOD GH TREATMENT AND CANCER RISKS (STUDY IV) 
Study IV, part of the SAGhE study, is a joint collaboration of eight European countries to 
create a large meta-cohort of childhood rhGH-treated patients with one of its objectives to 
investigate the long-term cancer risks in earlier treated patients. The major findings from the 
study was that the cancer mortality and incidence risks are highly associated with the 
underlying diagnosis for receiving rhGH treatment. The vast majority of cancer deaths and 
incident cases were a consequence of secondary malignancies in patients with a previous 
cancer diagnosis.  
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For the patients without a previous cancer diagnosis, a slight increase in cancer incidence was 
seen but not in cancer mortality. Further separating this group into subgroups of patients with 
isolated growth failure (GHD, SGA, and ISS) or other non-cancer diagnoses (such as 
multiple pituitary hormone deficiency, Turner syndrome, and skeletal dysplasias) showed that 
the former did not have an overall increased risk of cancer mortality or incidence but the 
latter did for both cancer mortality and incidence. In the patients with isolated growth failure, 
site-specific increased mortality risk of bone tumors was seen but no site-specific increased 
incidence risks. Even if significant, the number of deaths from bone tumors were few (n=3) 
creating wide confidence intervals for the three-fold increased SMR. For the other non-cancer 
diagnoses, no site-specific increased cancer mortality risk was seen, but increased site-
specific incidence risks for bone and bladder malignancies were found. 
The lack of large-scale long-term studies investigating cancer risks in previously rhGH-
treated patients greatly motivated this study. The follow-up studies to date have either had 
short follow-up time227,280-282 or small cohorts283,284 and have largely been based on post-
marketing databases, which rely on active reporting of adverse events by the treating 
physician227,280-282. Although many patient-years have been gathered in these databases, few 
conclusions of long-term safety can be drawn since the mean follow-up time per patient is 
only around four years. Considering that the development of malignancies often has quite a 
long lag period, an extensive follow-up time is needed to be able to detect any link to 
previous GH treatment. Most cancer types also occur in adulthood, and short follow-up time 
in still young patients would not provide any information on the risk of developing such 
malignancies later in life.  
Even if overall reassuring results in patients with isolated growth failure, the increased cancer 
mortality seen for bone tumors is somewhat disturbing since one of the main targets of GH, 
with abundant expression of the GH receptor, are the chondrocytes and osteoblasts (see 
section 2.3.1). For the other non-cancer diagnoses, increased incidence but not mortality for 
bone tumors was also seen, as well as several cases in both the mortality and incident 
analyses for the patients with a previous cancer diagnosis. A general increased risk of 
secondary neoplasms in childhood cancer survivors has been reported earlier by Sklar et al, 
and of note was the occurrence of osteogenic sarcomas in leukemia and lymphoma survivors 
treated with GH.285 An increased risk of CNS tumors, mostly meningiomas, was also reported 
in the same study and similar findings were reported by Bell et al, with osteogenic sarcoma 
being the second most common secondary neoplasm in cancer survivors.227 Both 
meningiomas and osteogenic sarcomas have been shown to express receptors for GH and 
IGF-I and modulation of the GH/IGF-I axis can affect the growth of these tumors in vitro and 
in vivo.286,287 However, regarding meningiomas, a separate report from the SAGhE cohort 
has shown that this finding is probably mainly due to cranial radiotherapy in childhood 
cancer survivors, with the role of GH treatment being more uncertain.288 
Another finding for the group with initial non-cancer diagnoses, apart from isolated growth 
failure, was the increased incidence of bladder cancers of which only very scarce previous 
 52 
data related to the GH/IGF-I-axis exist. In a case report from Japan, the recurrence of a 
superficial bladder tumor was described to be associated with periodically high levels of 
serum GH in an acromegaly patient.289 Bladder cancer has also been described to overexpress 
the growth hormone genes GH1 and GH2 by reports from the Oncomine database, a cancer 
microarray database of the cancer transcriptome in a large variety of cancer types.290 
Moreover, the detection of GHRH receptors in a series of bladder cancers have led to 
experiments with both GHRH agonist and antagonist showing tumor reducing capacities in 
mice xenografted with human bladder tumor cell lines for both substances, possibly by 
downregulation of GHRH receptors in both the cancer cells and the pituitary gland.291,292 A 
recent meta-analysis of cancer incidence in patients with acromegaly has also reported a 
slight, but increased, SIR for urinary tract cancers.293 However, the significance of our 
finding in the patients without a previous cancer diagnosis remains uncertain until more 
supporting data exist. 
A previous study on patients treated with human pituitary-derived GH has reported increased 
overall cancer mortality risks, particularly from colorectal cancer and Hodgkin’s 
lymphoma.256 Colorectal cancers have also been the main increased cancer type seen in 
acromegalic patients.294 However, in our study, very few cases of colorectal cancer were seen 
(n=6) with a significant increased standardized incidence ratio only in patients with an initial 
cancer diagnosis, based on two cases. For Hodgkin’s lymphoma, no overall increased risk 
was seen in any of the groups but for those with an initial non-cancer diagnosis, a highly 
significant increased incidence was seen with longer follow-up.  
The analyses of treatment dose and duration did not find any significant effects of higher 
cumulative dose or longer duration of treatment in patients with no previous cancer diagnosis, 
arguing against an overall effect on cancer risks in these patient groups. For isolated growth 
failure separately, increasing cancer incidence but not mortality was seen with longer 
treatment duration and follow-up time but not clearly for cumulative dose and not at all for 
mean dose. In those with an initial cancer diagnosis, higher mean dose was associated with 
increased cancer mortality but not cancer incidence. The interpretation of this finding remains 
unclear with arguments both for and against a possible causal explanation and further data are 
needed to clarify if higher GH doses might affect cancer survival in patients with a previous 
cancer diagnosis. 
 
6.4 STRENGTHS AND LIMITATIONS 
6.4.1 Study I and II 
The major strengths of study I and II, was the multitude of different metabolic investigations 
used to explore different metabolic parameters in this patient group of short children in 
comparison with controls of normal height, as well as the effects of different rhGH-doses 
over time. The in-depth examinations elucidated several key findings of the interplay between 
the GH/IGF-I-axis and other metabolic and hormonal systems, such as glucose metabolism 
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and insulin sensitivity. Not only were several differences between the groups and subgroups 
found, but also indications of the underlying mechanisms that created these differences. The 
group of short children was also strictly selected and examined in a consistent manner at the 
same research center which provided more robustness to the results and diminished the risk 
of introducing bias by different examiners and/or research centers. For study II, the design of 
having an external unit to handle both the block randomization process and the drug 
administration in unmarked packages could guarantee the blinding of dosing for both the 
patients, parents and study investigators.  
The limitations of study I and II were the size, which led to insufficient statistical power in 
possibly reaching significance for many of the non-significant trends of study I and restricted 
further subgroup analyses in study II. This could also increase the risk of making Type II 
errors in assuming the null hypothesis to be true when it is not, and we should always remind 
ourselves that the absence of proof does not equal proof of absence. The overall recruitment 
process was more difficult than anticipated when designing the study and due to the amount 
of different examinations carried out, each included patient was also very labor-intensive. A 
further limitation was the lack of information on how many eligible children were asked and 
declined participation at the other sites apart from the main recruitment site at the Karolinska 
University Hospital. However, only three out of the 35 included patients came from other 
sites and this limitation is unlikely to have affected the overall results of the study. For study 
II, the loss of follow-up in four patients is a limitation, but with almost 90% of the included 
patients fulfilling the two-year follow-up and the lack of association with dose allocation in 
those who terminated the study prematurely, it seems unlikely to have introduced any bias to 
the results.  
 
6.4.2 Study III 
Study III is a population-based nation-wide cohort study with 25 years of follow-up, covering 
almost all Swedish rhGH-treated patients from the introduction of recombinant GH in 1985 
to the end of 2010. Over 3,400 patients with GHD, SGA or ISS, and more than 50,000 
controls were included in the analyses of possible cardiovascular risk in childhood rhGH-
treated patients.  
Through extensive linkage of data from numerous Swedish healthcare and population-based 
registries, using each patient’s and control’s unique personal identity number, we were able to 
address this question in a more profound and detailed way than has been previously done. 
The controls were randomly selected by Statistics Sweden from the general population and 
matched to each patient based on sex, age and geographical region and information not only 
regarding the patients and controls but also on the parents was gathered in order to adjust for 
socioeconomic factors within the family. Fifteen controls for each patient were selected and 
other important covariates for the adjusted analyses, such as birth characteristics (birth length, 
birth weight and gestational age), could also be obtained for the whole cohort. Outcome data 
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were retrieved from the Swedish National Patient Register and Swedish Cause of Death 
Register, which both have very high and nearly complete coverage rates, keeping the 
incompleteness of follow-up to a minimum. All outcome data were independently and 
prospectively collected within the registries, minimizing different types of information bias.  
To further strengthen our analyses, we also gathered information on height for the control 
group from several sources, in order to adjust for this covariate and thereby also controlling 
for other height-associated confounding factors which are hard or impossible to measure. We 
could thus not only adjust for birth characteristics, age, sex, geographical and socioeconomic 
factors, but also for height at study inclusion, in our attempt to isolate the effects of GH 
treatment on the analyzed outcomes.  
The major limitation of the study is the possibility of confounding by indication, where the 
underlying reason for starting GH treatment might also be linked to the risk of later 
cardiovascular events. We tried to handle such potential bias by the measures described 
above and also by performing dose-response analyses to investigate if treatment exposure 
was of relevance or not for the risk of future events. However, it is impossible to completely 
avoid the possibility of residual confounding, and the associations described should be seen 
in this light and not be viewed as evidence of causal relationships.  
Another limitation concerns the fact that our cohort is still young and we only have data on 
long-term effects up to young adult ages. This limitation restricts us to infer about risks in 
later adulthood and makes further surveillance important for such questions to be answered. 
Being a young cohort also introduces issues of statistical power; even if we gathered a large 
cohort, the outcome we study is still quite uncommon in young individuals and therefore the 
number of events are low. This weakens the precision in our estimates and makes some of the 
stratified subgroup analyses underpowered. The continuous follow-up to older ages is thus 
also important for this aspect, since cardiovascular events will become more frequent in later 
adulthood.  
 
6.4.3 Study IV 
The collaboration of several countries to create a large cohort of previously rhGH-treated 
patients has been a major effort and has provided valuable information on such rare events as 
cancer incidence and mortality in a still quite young group of patients. Another strength of 
this study, apart from its size, is the extensive follow-up time, which is necessary to 
investigate events with an expected long lag period. The high completeness of the study, 
through gathering of data from national registries with high coverage rates, has in addition 
limited the amount of loss to follow-up and having a fixed end date rather than censoring on 
last medical visit has reduced potential bias, since medical contacts often are associated with 
the health status of the patient seeking care.  
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The risk classification of patients and presentation of data based on different subgroups of 
patients have also been important, since the underlying diagnosis for receiving GH treatment 
has a major impact on cancer risks. Moreover, the analysis by dose and duration categories 
has not been done in previous studies and is essential to investigate any associations between 
treatment exposure and cancer outcomes.  
The major limitation of the study is the lack of an untreated control group. All interpretations 
of relative risks must always carefully consider the properties of the comparison group. The 
extremely high SMRs and SIRs of the patients with a previous cancer diagnosis were to be 
expected since the comparison group was the general population and it is difficult to assess to 
what degree, if any, GH treatment has contributed. Thus, the analyses with dose and duration 
as well as particular patterns of site-specific malignancies become essential. 
Similarly, for the other risk groups of isolated growth failure, including GHD, ISS and SGA, 
or the other non-cancer diagnoses, unadjusted comparisons with a general population are less 
than ideal. These groups might as well have underlying factors associated with the outcome 
that could distort and confound the associations presented. However, such underlying factors 
could affect the risk in both ways, not only imply an inherent increased risk for the outcome 
but also a possible inherent decreased risk. An argument could perhaps be made that 
considering the known association with increased height295-297 as well as increased IGF-I 
levels221,251,298,299 and cancer risks, a short untreated group should a priori be expected to 
have a lower baseline cancer risk than the general population of taller stature. If this would be 
the case, then a similar risk as the background population after treatment would for these 
patient groups actually mean that their risk has increased from a hypothetically lower baseline 
risk.  
Furthermore, in the low-risk group of isolated growth failure, severe diagnoses and previous 
cancer diagnoses have been filtered out but such diagnoses all remain in the comparison 
group of the general population, albeit diluted. Thus, when comparing a patient group where 
by definition no previous cancer may exist to a population where all childhood cancer still 
remains, even if rare and diluted as in the general population, those cases might still 
contribute to such a degree that the comparisons with a group in which such diagnoses have 
been filtered out becomes inaccurate.  
There are also several other limitations to the study, such as the lack of GH treatment 
information beyond pediatric ages, lack of information on IGF-I levels, and still quite few 
individuals beyond the age of 35 years, restricting any conclusions of cancer risks in older 
ages. Studying rare events also creates issues with statistical power, as for study III, with 
more uncertainty in the results illustrated by wide confidence intervals. Lastly, including data 
from eight different countries creates a complexity to the aggregated dataset but, at the same 
time, also increases the external validity of the study and was an inevitable element of 
creating a large enough cohort to achieve sufficient statistical power for these analyses. 
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7 CONCLUSIONS AND FUTURE PERSPECTIVES 
The main conclusions of each study are presented below: 
Study I 
 Few overall metabolic differences were seen between short prepubertal children with 
stimulated GH peak levels of 7-14 µg/L and healthy age- and sex-matched controls of 
normal height and weight. 
 
 The subgroup of short prepubertal children with the lowest stimulated GH peak level 
(<10 µg/L) differed from both the other short children and controls, with lower levels 
of fasting insulin and signs of increased insulin sensitivity.  
 
Study II 
 A dose-dependent effect of GH treatment on several metabolic parameters was found 
in the short children from Study I and in particular for the high dose group (100 
µg/kg/d) regarding fasting insulin levels and indices of insulin sensitivity. All groups 
showed decreased insulin sensitivity during the study but the low (11 µg/kg/d) and 
standard (33 µg/kg/d) dose groups remained within normal reference ranges for 
fasting insulin and HOMA-IR.  
 
 The high dose group showed the largest height SDS increase and increased levels of 
IGF-I and also significantly raised fasting glucose levels and HbA1c over the two-year 
study period. Effects on fasting glucose and HbA1c were not seen in the low or 
standard dose group.  
 
Study III 
 Childhood GH treatment due to GHD, SGA or ISS, was associated with higher 
adjusted hazard ratios for overall and severe cardiovascular events later in life. The 
elevated risks ranged from around half to double for the different treatment groups 
with the SGA group and females showing the highest increased risks.  
 
 In relation to dose and duration of treatment, the highest relative risks were seen for 
those with the longest duration and the highest cumulative dose but no association was 
found between higher mean daily dose and increased cardiovascular risks. A 
significant trend was additionally found for treatment duration but not for cumulative 
or mean dose. 
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 The absolute risks of cardiovascular events were low in both patients and controls. 
 
Study IV 
 Overall cancer mortality and incidence risks were highly related to the underlying 
diagnosis for GH treatment. For patients with a previous cancer diagnosis, markedly 
increased cancer mortality and incidence risks were found in GH-treated patients 
compared to the general population. For patients with GHD, ISS or SGA, no overall 
increased cancer mortality or incidence risks were seen. For other non-cancer 
diagnoses, such as Turner syndrome or multiple pituitary hormone deficiency, slightly 
increased overall cancer mortality and incidence risks compared with the general 
population were found.  
 
 For the patients with no previous cancer diagnosis, a site-specific increased mortality 
risk of bone tumors was found in the GHD, ISS and SGA patients and a site-specific 
increased incidence risks for bone and bladder cancer in patients with other non-
cancer diagnoses, although based on few cases.  
 
 In GHD, ISS and SGA patients, a significant trend of higher cancer incidence was 
seen with longer follow-up since first treatment and duration of treatment but not with 
mean dose or regarding cancer mortality. In patients with an initial cancer diagnosis, 
higher mean daily dose was associated with increased cancer mortality but not with 
increased cancer incidence. 
 
 For the site-specific analyses, longer follow-up was associated with a decreasing risk 
of CNS tumors in patients with an initial cancer diagnosis, and an increasing risk for 
Hodgkin’s lymphoma in non-cancer patients. 
 
 
Future perspectives and concluding remarks 
The results of the studies presented in this thesis provide some answers but also bring with 
them many new questions and several ideas of new projects within this field have emerged 
along the way, of which some will be presented below.  
Regarding the metabolic characteristics in patients with different levels of activity in the 
GH/IGF-axis, an expansion of study I and II, also including patients with stimulated GH 
levels <7 µg/L would be of great interest. To characterize the metabolic profile over the 
whole spectrum of GH secretion would be valuable for our understanding of the metabolic 
properties of GH and GH treatment. Additionally, to further investigate the treatment effects, 
having a group of patients also randomized to no treatment, as a comparison group within 
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study II, would have been useful to better separate the physiological metabolic changes 
occurring in this age of transition into puberty from effects of various GH doses. With respect 
to the strong links with fasting insulin and insulin sensitivity found, analyzing other 
parameters, such as for example IGFBP1, known to be related to hepatic insulin sensitivity, 
could also have been valuable to improve our understanding of such a connection.  
For study III and IV, the continuous surveillance and follow-up of these patient cohorts are 
required in order to have a more complete answer to the long-term safety of childhood GH 
treatment. Both cohorts are still quite young and what long-term risk that might occur in later 
adulthood and older ages are still uncertain. With older age, increasing number of cancer and 
cardiovascular events are expected, which would improve the statistical power and precision 
of future comparisons. Having information of more covariates of importance, such as IGF-I 
levels in the patient group, would also have been very valuable in order to investigate if 
cancer risks are related to IGF-I levels. Such information could also have important clinical 
implications in our dosing of GH to different patient groups.  
For study IV, to further analyze cancer risks with more suitable comparison groups for the 
different patient groups would be of great value. Having a similar possibility to adjust for 
several possible confounders, as was done in study III, would improve the comparisons and 
would have created more informative results regarding the relative risks. To create a 
randomized trial with life-long follow-up would of course be ideal, but since this option is not 
available due to practical, ethical and economic reasons, our best alternative is well-designed 
observational studies.  
As a concluding remark, the clear metabolic effects and the indications of possible future 
risks further emphasize the need of continuous follow-up of GH-treated patients so that our 
understanding and knowledge can continue to increase regarding the metabolic effects and 
long-term safety of childhood GH treatment. 
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